Modules 2–5 plus Expansion, full verbatim text — including in-ER regimens, discharge plans and red flags — with every brand linked to your local store (index). Also see: Pediatric emergency guide (Module 1) →
DAPT loading · weight-based enoxaparin · statin within 24 h
Background talk — presentation, triage & evidence
Clinical Presentation & Risk Stratification Pathophysiology: Rupture or erosion of an unstable, thin-cap fibroatheroma (TCFA) leading to platelet adhesion, activation, aggregation, and localized generation of thrombin and fibrin networks.
This causes either complete transmural coronary occlusion (STEMI) or partial/intermittent flow obstruction (NSTE-ACS: Unstable Angina/NSTEMI).
Triage & Diagnostics
ER Triage & Diagnostics: Immediate 12-lead ECG acquired and interpreted within ≤10 minutes of arrival. High-sensitivity cardiac Troponin (hs-cTn) at 0 and 1–2 hours.
STEMI Criteria
STEMI Criteria: New ST-segment elevation at the J-point in ≥2 contiguous leads: ≥2.5 mm in men <40, ≥2.0 mm in men ≥40, or ≥1.5 mm in women in leads V2 – V3 V2 –V3; or ≥1.0 mm in other contiguous leads; or new Left Bundle Branch Block (LBBB) with Sgarbossa/Smith-modified criteria.
Risk Stratification (GRACE/TIMI)
GRACE/TIMI Risk Scores: Calculate early to stratify NSTE-ACS into immediate invasive (<2 hours), early invasive (<24 hours), or selective invasive pathways.
Evidence & Rationale
Comparative Evidence & Pharmacological Rationale — Antiplatelet Therapy: Dual Antiplatelet Therapy (DAPT) Selection — Aspirin Foundation: Irreversibly acetylates platelet Cyclooxygenase-1 (COX-1), suppressing thromboxane A 2 (TXA 2) synthesis for the lifespan of the platelet (7–10 days).
A loading dose of non-enteric coated chewable aspirin (162–325 mg) achieves >95% COX-1 inhibition within 15–20 minutes.
P2Y12 Choice
P2Y12 Receptor Antagonists — Ticagrelor vs. Clopidogrel: The PLATO Trial (Wallentin et al., NEJM): Ticagrelor (BRILINTA) showed a statistically significant reduction in the primary composite endpoint of death from vascular causes, MI, or stroke compared to clopidogrel (9.8% vs. 11.7%; p<0.001), including a reduction in all-cause mortality (4.5% vs. 5.9%; p<0.001) and definite stent thrombosis, without an increase in overall major bleeding.
Pharmacokinetics
Pharmacokinetics: Clopidogrel (PLAVIX, CLOVIX) is a prodrug requiring a two-step hepatic bioactivation via cytochrome P450 enzymes (CYP2C19, CYP3A4).
Up to 30% of patients carry CYP2C19 loss-of-function alleles (*2, *3), resulting in clopidogrel resistance (high on-treatment platelet reactivity).
Ticagrelor is a direct-acting, reversibly binding cyclopentyltriazolopyrimidine that does not require metabolic activation, providing more rapid, potent, and predictable platelet inhibition.
Prasugrel
Prasugrel Considerations: The TRITON-TIMI 38 trial demonstrated the superiority of Prasugrel (PRASUGREL TEVA) over Clopidogrel in reducing ischemic events in patients undergoing PCI.
Prasugrel Warning
However, it carries a black-box warning: it is contraindicated in patients with a history of stroke or TIA and shows no net clinical benefit in patients aged ≥75 years or weight <60 kg due to fatal intracranial and major bleeding.
Parenteral Anticoagulation
Parenteral Anticoagulation: Enoxaparin (LMWH) vs. Unfractionated Heparin (UFH) — The SYNERGY and ATOLL Trials: Low Molecular Weight Heparin (Enoxaparin; CLEXANE, ENOXAPARIN LEDRAXEN) demonstrates a more predictable anticoagulant response than UFH due to lower binding to plasma proteins, macrophages, and endothelial cells.
It yields a higher ratio of anti-Factor Xa to anti-Factor IIa (thrombin) activity (3.8:1 vs. 1:1 for UFH).
In the ATOLL trial (STEMI undergoing primary PCI), IV enoxaparin significantly reduced the composite endpoint of 30-day death, recurrent ACS, or major bleeding compared to UFH (RR 0.83).
In NSTE-ACS, subcutaneous enoxaparin reduces composite ischemic outcomes with no requirement for routine aPTT monitoring.
High-Intensity Statin
High-Intensity Statin Pleiotropy The PROVE-IT TIMI 22 Trial: High-dose statin therapy initiated within the first 24 hours of ACS stabilizes vulnerable atherosclerotic plaques, reduces vascular inflammation, suppresses tissue factor expression, and improves endothelial nitric oxide bioavailability within hours—effects independent of immediate LDL lowering.
Dose: 300 mg PO stat (Take 3 tablets of 100 mg simultaneously).
Instructions: Patient must chew the tablets thoroughly before swallowing to bypass the enteric coating and accelerate buccal/gastric transmucosal absorption (Cmax <20 min).
P2Y12 Receptor Antagonist (Choose Option A unless contraindicated): Option A (First-Line Guideline Preferred — Ticagrelor):
Dose: 180 mg PO stat (Two 90 mg tablets taken together).
Option B (Alternative — Clopidogrel; if patient has high bleeding risk, history of intracranial hemorrhage, or is on oral anticoagulation):
Formulary Match: PLAVIX 75MG (MSS) or CLOVIX 75 TAB 30 (BPC) or CLOPIDOGREL 75 MG TAB (Teva).
Dose: 600 mg PO stat (Eight 75 mg tablets swallowed together for PCI/STEMI) or 300 mg PO stat (if conservative management or age >75 receiving fibrinolytics).
Option C (Prasugrel — For STEMI undergoing planned PCI; non-elderly, weight >60 kg, no stroke/TIA history):
Formulary Match: CLEXANE 100MG SAFETY LOCK SYR PREFIL (100 mg/1 ml), CLEXANE 80MG, CLEXANE 60MG, CLEXANE 40MG (MSS) or ENOXAPARIN LEDRAXEN (True med) or INHIXA (JePharm).
STEMI Dosing Protocol — If Age <75 Years: Single 30 mg IV bolus, immediately followed 15 minutes later by 1 mg/kg Subcutaneously (max 100 mg for the first two SC doses), then 1 mg/kg SC every 12 hours.
If Age ≥75 Years: No IV bolus; initiate directly with 0.75 mg/kg Subcutaneously every 12 hours (max 75 mg for first two doses).
Renal Adjustment (CrCl <30 ml/min CrCl<30 ml/min): 1 mg/kg SC once every 24 hours.
NSTE-ACS Protocol: 1 mg/kg Subcutaneously every 12 hours (no IV bolus required).
Alternative (Unfractionated Heparin - Preferred if patient is proceeding immediately to CABG or has CrCl <15 ml/min CrCl<15 ml/min):
Formulary Match: HEPARIN INJECTION BP 5000 UNITS/ML 5ML (True med) or Heparin Sodiom 5000IU (MSS).
Dose: IV bolus 60 units/kg (max 4000 units), followed by maintenance infusion of 12 units/kg/hour (max 1000 units/hour), titrated to maintain target aPTT at 1.5–2.0×1.5–2.0× control (50–70 seconds).
Dose: 20 mg PO. (Note: In the acute resuscitation bay, sublingual nitroglycerin spray/tablets are standard if available; if using isosorbide mononitrate orally, titrate carefully).
Critical Hemodynamic Preconditions: Systolic BP must be >100 mmHg; Heart Rate 50–100 bpm.
Strictly contraindicated if right ventricular (RV) infarction is suspected (inferior STEMI with leads V3R/V4R elevation) or if patient used PDE-5 inhibitors in the preceding 24–48 hours (SILDENAFIL, CIALIS, LEVITRA).
Analgesia (For Refractory Severe Chest Pain Unresponsive to Nitrates)
Dose: 2–4 mg slow IV push every 5–15 minutes titrated to pain control.
Clinical Caution: The CRUSADE and IMPRESSION studies showed morphine delays gastric emptying, decreasing Cmax and delaying the antiplatelet absorption of oral P2Y12 inhibitors (Ticagrelor/Clopidogrel).
Use only for breakthrough ischemic pain unresolved by anti-ischemic medical therapy.
Early High-Intensity Plaque-Stabilizing Statin
Formulary Match: Lipitor 80mg 30TAB (Beit Hanina) or LIPIDEX 40 MG (BPC, 2 tabs=80 mg) or CRESTOR 20MG (Omnipal, 2 tabs=40 mg) or ROXARDIO 40 mg Tab (Masrouji).
Dose: Atorvastatin 80 mg PO stat (or Rosuvastatin 40 mg PO stat).
Following emergency PCI or inpatient stabilization of ACS, the patient is transitioned to secondary prevention pharmacotherapy to mitigate recurrent atherothrombotic events and ventricular remodeling:
Sig: Take 1 tablet by mouth once daily with lunch.
Duration: Indefinite (Lifelong).
Note: In the presence of Ticagrelor, daily aspirin dose should NOT exceed 100 mg; high maintenance doses (>100 mg) antagonize the clinical efficacy of Ticagrelor.*
Sig: Take 1 tablet by mouth once daily, 30 minutes before breakfast.
Indication: Mandatory gastroprotection for DAPT patients with moderate-to-high gastrointestinal bleeding risk.
Red Flags & Safety Warnings • Inferior STEMI/Right Ventricular (RV) Infarction: • In patients with ST elevation in II, III, and aVF, obtain right-sided leads (V3R, V4R). • If ST elevation ≥0.5–1.0 mm is present in V4R, the right ventricle is ischemic and preload-dependent. • Nitrates, morphine, and diuretics are contraindicated; their administration can induce sudden severe hypotension and cardiogenic shock. • Treat hypotension in RV infarction with IV isotonic crystalloid boluses (SODIUM CHLORIDE 0.9%) to expand RV filling pressures. • Ticagrelor Dyspnea vs. Pulmonary • Edema: Ticagrelor causes self-limiting, non-heart failure dyspnea in up to 15% of patients due to inhibition of adenosine reuptake by erythrocytes (elevating endogenous adenosine levels). • Differentiate from pulmonary edema: ticagrelor dyspnea occurs without orthopnea, pulmonary rales, or hypoxemia, typically peaking within 3–5 days.
Clinical Presentation & Hemodynamic Phenotyping Pathophysiology: Abrupt increase in left ventricular end-diastolic pressure (LVEDP) transmitted backward into the pulmonary venous system.
When pulmonary capillary wedge pressure exceeds oncotic pressure (>20–25 mmHg), fluid transudates into the pulmonary interstitial space and alveoli, causing ventilation-perfusion mismatch, intrapulmonary shunting, and respiratory distress.
Comparative Evidence & Pharmacological Rationale Loop Diuretics: High-Dose Bolus vs. Continuous Infusion (The DOSE Trial) The DOSE Trial (Felker et al., NEJM): In patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when IV furosemide was administered via continuous infusion versus intermittent bolus every 12 hours.
Dose Intensity: Patients assigned to high-dose strategies (2.5×2.5× their previous oral daily maintenance dose administered IV) showed greater net fluid loss, more rapid relief of dyspnea, and fewer serious adverse events than low-dose (1×1× oral dose IV) without causing long-term permanent renal impairment.
Vascular Effects: IV furosemide produces a rapid venodilatory response mediated by prostaglandin release within 5–15 minutes, lowering right atrial and pulmonary wedge pressures before the onset of diuretic action (which starts at 30 minutes).
Vasodilators in Flash Edema
Vasodilators vs. High-Dose Diuretics in Flash Pulmonary Edema Afterload Reduction: In hypertensive acute pulmonary edema ("flash pulmonary edema", preserved ejection fraction, SBP >160–180 mmHg), the primary problem is systemic vasoconstriction and afterload mismatch, not total-body volume overload.
Evidence: Randomized clinical studies (Cotter et al., Lancet) demonstrate that high-dose IV nitrates combined with low-dose furosemide is superior to high-dose furosemide alone in controlling pulmonary edema, reducing mechanical ventilation rates, and limiting myocardial infarction size.
Inotropic Selection (DOREMI)
Inotropic Selection in Cardiogenic Shock: Dobutamine vs. Milrinone
Dobutamine: Direct β1 -agonist with mild β2 -mediated peripheral vasodilation; increases myocardial contractility and stroke volume.
The DOREMI Trial (NEJM 2021):
Evaluated Dobutamine versus Milrinone (phosphodiesterase-3 inhibitor) in cardiogenic shock.
Found no significant difference between the drugs regarding in-hospital death, resuscitated cardiac arrest, renal replacement therapy, or mechanical circulatory support.
Dobutamine is preferred when renal impairment is present (eGFR <30 ml/min eGFR<30 ml/min) due to milrinone’s exclusively renal clearance and prolonged half-life.
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Dosing Stratification: Loop Diuretic Naive Patient: 40 mg IV slow bolus (administered over 2–3 minutes).
Chronic Oral Furosemide User: Administer an IV dose equal to 2.0–2.5×2.0–2.5× their daily oral maintenance dose.
Calculation: If patient takes 40 mg PO daily at home → → Administer 80–100 mg IV stat (8–10 ml of 10 mg/ml solution).
Evaluation of Response: Check spot urine sodium at 2 hours and total urine output at 6 hours.
Failure to Respond: If 2-hour urine sodium is <50–70 mEq/L<50–70 mEq/L or hourly urine output is <100–150 ml/hr, double the IV furosemide dose (e.g., escalate from 80 mg to 160 mg IV push).
2. Afterload & Preload Reducers (Vasodilators — SBP >110 mmHg) Nitrates (Oral Formulation for ER Use in Absence of Dedicated IV Nitro Line):
Clinical Effect: Promotes venous capacitance bed pooling, lowers right and left ventricular filling pressures, and reduces myocardial oxygen consumption.
3. Inotropic Support for Cardiogenic Shock/"Cold & Wet" Phenotype (SBP <90 mmHg, Hypoperfusion)
Preparation & Dilution: Add 250 mg (20 ml) to 230 ml of DEXTROSE 5% ALISON IV INFUSION 250ML (Alison) or SODIUM CHLORIDE 0.9% 250ML BOTTLE (Nobel Store) to achieve a final concentration of 1000 mcg/ml (1 mg/ml).
Infusion Rate & Titration: Initiate at 2.5–5.0 mcg/kg/min IV via a dedicated infusion pump.
Titrate by 2.5 mcg/kg/min every 15 minutes based on cardiac index, blood pressure, urine output, and peripheral perfusion parameters (usual range: 2.5–15 mcg/kg/min, max 20 mcg/kg/min).
Concurrent Vasopressor (If Mean Arterial Pressure [MAP] <65 mmHg)
Criteria for Discharge: Euvolemia achieved (absence of peripheral edema, jugular venous distention ≤3 cm above sternal angle, orthopnea resolved), transitioned to stable oral diuretics for >24 hours, renal function stable:
Initiation of Sacubitril/Valsartan in-hospital post-stabilization significantly reduces NT-proBNP and rehospitalization rates compared to Enalapril alone.
Washout Rule: If patient was receiving an ACE-inhibitor, enforce a strict 36-hour washout period before first Entresto dose to prevent life-threatening angioedema.*
Sig: Take 1.25 mg to 2.5 mg by mouth once daily in the morning.
Rule: Initiate or up-titrate beta-blockers ONLY when euvolemia is fully restored; starting beta-blockers in decompensated wet/cold states worsens acute heart failure.*
Sig: Take 1 tablet by mouth once daily in the morning.
Evidence (DAPA-HF/EMPEROR-Reduced)
SGLT2 inhibitors provide immediate osmotic diuresis, reduce cardiovascular mortality by 18%, and reduce heart failure hospitalizations by 30%, regardless of whether diabetes mellitus is present.
Monitor potassium and renal panel at 1 and 4 weeks.
Red Flags & Safety Warnings • Routine Morphine Harm: Do not administer routine IV morphine in acute decompensated heart failure. • The ADHERE registry analysis (n>147,000) demonstrated that morphine use was independently associated with an increased need for mechanical ventilation, longer ICU stays, and higher in-hospital mortality (adjusted OR 1.21). • SGLT2 Inhibitor Glycemic Safety: While SGLT2 inhibitors are effective in heart failure, monitor for euglycemic Diabetic Ketoacidosis (euDKA) in patients with diabetes who are fasting or acutely ill; discontinue during acute severe sepsis.
Focus on rate control, thromboembolic stroke risk assessment (CHA2DS2-VASc), and determination of AF onset duration (<48 hours vs. >48 hours >48 hours/unknown).
Rate Control — BB vs. CCB
Comparative Evidence & Pharmacological Rationale Beta-Blockers vs. Non-Dihydropyridine Calcium Channel Blockers (Diltiazem/Verapamil) Preserved Ejection Fraction (LVEF ≥40% LVEF≥40%): Both nondihydropyridine CCBs (Diltiazem) and β-blockers (Metoprolol, Bisoprolol) provide effective rate control by prolonging AV nodal refractoriness.
Multiple ER trials demonstrate Diltiazem achieves target ventricular rate (<100–110 bpm) more rapidly than IV Metoprolol (median time: 15–20 minutes vs. 40–60 minutes; success rate >85% vs. ≈60%).
Reduced Ejection Fraction (LVEF <40% LVEF<40% or Acute Decompensated Heart Failure): Non-dihydropyridine CCBs are contraindicated due to negative inotropic effects that can trigger cardiogenic shock and exacerbate pulmonary edema.
In patients with heart failure or an unknown ejection fraction, β-blockers (cautious, low-dose) or Amiodarone (AMIOCARD, PROCOR) is preferred.
48-Hour Cardioversion Rule
The 48-Hour Cardioversion Rule & Thromboembolic Embolization If AF duration is >48 hours (or undetermined), immediate electrical or chemical cardioversion is contraindicated without prior transesophageal echocardiography (TEE) or 3 weeks of therapeutic anticoagulation.
Conversion back to sinus rhythm allows the stunned left atrial appendage to contract, which can dislodge a pre-existing thrombus and cause an embolic ischemic stroke.
Focus on ventricular rate control and initiate immediate systemic anticoagulation.
Direct Oral Anticoagulants (DOACs) vs. Warfarin (Coumadin)
DOAC Superiority (ARISTOTLE & ROCKET-AF Trials): Apixaban (Eliquis, APIXABAN TEVA) and Rivaroxaban (XARELTO) are superior or non-inferior to Warfarin (COUMADIN) in preventing stroke and systemic embolism in non-valvular AF, and they reduce intracranial hemorrhage by ≈50%.
DOACs achieve therapeutic anticoagulation within 2–4 hours of oral administration without requiring INR monitoring.
Formulary Match: DARONEX 200MG TAB (BPC) or AMIOCARD 200MG/30TABS (Syam) for oral loading; for acute parenteral administration:
IV Amiodarone loading: Parenteral Dose (Emergency Protocol): 300 mg IV loading dose (or 5 mg/kg) diluted in 250 ml of DEXTROSE 5% ALISON IV INFUSION 250ML (Alison) (Amiodarone is incompatible with Normal Saline and precipitates).
Infuse IV over 30 to 60 minutes via peripheral line or central venous line.
Maintenance Infusion: Follow with a continuous infusion of 900 mg over 24 hours (1 mg/min for 6 hours, then 0.5 mg/min for 18 hours).
CHA2DS2-VASc Score: If ≥2 in males or ≥3 in females, anticoagulation is strongly indicated.
Option 1: Apixaban (First-Line Factor Xa Inhibitor):
Formulary Match: Eliquis 5 mg 60 TAB (Beit Hanina) or APIXABAN TEVA 5 MG 60 TAB (Teva) or IXABAN 5 MG 60 TAB (BPC) or QUEST 5MG TABLET (Pharmacare).
Dose: 5 mg PO twice daily.
Dose Reduction Criteria (2.5 mg PO BID): Reduce dose if patient has ≥2 of the following: Age ≥80 years, Serum Creatinine ≥1.5 mg/dL (), or Body Weight ≤60 kg (Eliquis 2.5 mg/QUEST 2.5MG).
Option 2: Rivaroxaban (Factor Xa Inhibitor — Once Daily):
Formulary Match: XARELTO 20MG 28 F.C.TAB (CEZAR) or RIVOXAR 20MG TABLETS (Jepharm) or RIVAR 20 MG 28 TAB (Teva).
Dose: 20 mg PO once daily taken with the evening meal. Renal Adjustment (CrCl 15–49 ml/min): Reduce to 15 mg PO once daily with dinner (XARELTO 15MG, RIVAR 15 MG).
Discharge & Outpatient Transition Regimen
Criteria for Discharge: Resting ventricular heart rate <100–110 bpm sustained for >4 hours, asymptomatic, no acute coronary ischemia or heart failure decompensation, anticoagulation instituted with follow-up scheduled.
Red Flags & Safety Warnings • Pre-Excitation/Wolff-Parkinson-White (WPW) Syndrome: • In patients with AF and ventricular pre-excitation (wide, bizarre, irregular QRS complexes on ECG representing antegrade conduction down an accessory pathway): AV-nodal blocking agents (Beta-blockers, Diltiazem, Verapamil, Digoxin, and IV Amiodarone) are contraindicated. • Blocking the AV node diverts all rapid atrial impulses down the accessory bypass tract, which lacks a decremental conduction delay, precipitating ventricular fibrillation (VF) and cardiac arrest. • Management: Perform immediate synchronized electrical cardioversion, or use IV Procainamide.
Hypertensive Urgency: Severe blood pressure elevation (typically Systolic BP ≥180 mmHg BP≥180 mmHg and/or Diastolic BP ≥120 mmHg BP≥120 mmHg) without clinical or laboratory evidence of acute target-organ damage.
Management Strategy: Does not require immediate parenteral ER reduction.
Precipitous lowering causes cerebral, coronary, or renal hypoperfusion.
Manage with oral medications and outpatient titration over 24–48 hours.
Hypertensive Emergency
Hypertensive Emergency: Severe BP elevation with acute, life-threatening target-organ dysfunction:
Comparative Evidence & Pharmacological Rationale — General Rate of BP Lowering in Hypertensive Emergencies (AHA/ACC Guidelines): In the absence of specific conditions (such as aortic dissection or acute ischemic stroke), mean arterial pressure (MAP) should be lowered by no more than 20–25% within the first hour.
If stable, reduce toward 160/100–110 mmHg over the following 2 to 6 hours, then cautiously toward normal over the next 24 to 48 hours.
Autoregulatory curves in chronic hypertension are shifted to the right; rapid normalization below the autoregulatory plateau triggers cerebral hypoperfusion, ischemic infarction, and acute tubular necrosis.
The Hemodynamic Requirement: In acute type A or B aortic dissection, BP must be reduced aggressively and rapidly.
Target: Systolic BP <120 mmHg and Heart Rate <60 bpm within 10 to 20 minutes.
Why Beta-Blockers Must Precede Vasodilators: Shear stress on the aortic wall (ΔP/Δt) is driven by ventricular contractility and heart rate.
Administering a direct vasodilator (such as hydralazine or nitroprusside) prior to adequate β -blockade induces reflex tachycardia and increased stroke volume, escalating shear forces and causing catastrophic propagation of the dissection flap or aortic rupture.
Parenteral Choice: IV Labetalol (LABETALOL AMP 5MG/ML) provides combined α1 - and nonselective β1/β2 -blockade (1:7 ratio IV), reducing both peripheral resistance and cardiac inotropy/chronotropy simultaneously.
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Intermittent Bolus Protocol: Administer initial dose of 20 mg IV push over 2 minutes.
Reassess BP every 5–10 minutes.
If target BP not reached, administer 40–80 mg IV every 10 minutes (e.g., 20 mg → 40 mg → 80 mg → 80 mg 20 mg→40 mg→80 mg→80 mg) until target BP is achieved (Cumulative maximum bolus: 300 mg).
Continuous IV Infusion Alternative: Dilute 200 mg (40 ml) in 160 ml of SODIUM CHLORIDE 0.9% to make 1 mg/ml concentration.
Initiate infusion at 1–2 mg/min (60–120 ml/hr); titrate upward by 1 mg/min every 15–30 minutes to a maximum rate of 8–10 mg/min. Contraindications: Severe bradycardia (HR <50 bpm HR<50 bpm), second- or third-degree AV block, active asthma/bronchospasm, severe acute decompensated heart failure.
2. Oral Protocol: Hypertensive Urgency (Asymptomatic Severe Hypertension) Do NOT use rapid-acting sublingual nifedipine (causes uncontrolled hypotension, reflex tachycardia, stroke, and death).
Initiate or adjust gradual-onset oral therapies: Option 1:
Red Flags & Safety Warnings • Ischemic Stroke BP Thresholds: In acute ischemic stroke, do not lower blood pressure unless it exceeds >220/120 mmHg (or >185/110 mmHg if the patient is a candidate for IV thrombolysis with alteplase/tenecteplase). • The ischemic penumbra relies on collateral perfusion pressure; dropping the MAP expands the cerebral infarction. • Preeclampsia/Eclampsia Warning: ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and direct renin inhibitors are strictly teratogenic and contraindicated in pregnancy. • For pregnant patients presenting with severe gestational hypertension or preeclampsia (BP ≥160/110 mmHg), use IV Labetalol or oral Methyldopa (ALDOPA 250 MG, Jepharm), combined with IV Magnesium Sulfate (MAGNESIUM SULFATE KALCEKS 50%) for seizure prophylaxis.
Clinical Presentation & Surviving Sepsis Campaign Definitions — Pathophysiology: Dysregulated host systemic inflammatory response to an invasive infection, resulting in endothelial dysfunction, glycocalyx shedding, diffuse microvascular permeability, microvascular thrombosis, vasoplegia, cellular metabolic dysfunction, and multi-organ failure.
Definitions (Sepsis-3)
Sepsis: Suspected or documented infection plus acute organ dysfunction characterized by an increase in Sequential Organ Failure Assessment (SOFA) score ≥2 points (or quickSOFA ≥2: RR ≥22 breaths/min RR≥22 breaths/min, altered mental status [GCS <15 GCS<15], Systolic BP ≤100 mmHg BP≤100 mmHg).
Septic Shock: Sepsis with persistent hypotension requiring vasopressors to maintain Mean Arterial Pressure MAP ≥65 mmHg MAP≥65 mmHg, accompanied by a serum lactate level >2 mmol/L>2 mmol/L despite adequate, aggressive crystalloid fluid resuscitation.
Evidence — Fluids (SMART / SALT-ED)
Comparative Evidence & Pharmacological Rationale Resuscitation Fluids: Balanced Crystalloids vs. Normal Saline (0.9% NaCl) The SMART and SALT-ED Trials (Semler et al., NEJM): Large-scale randomized trials demonstrated that balanced crystalloids (such as Ringer's Lactate; COMPOUND SODIUM LACTATE, RINGER LACTATE S.A.L.F) are superior to 0.9% NaCl in critically ill patients, reducing the 30-day composite outcome of Major Adverse Kidney Events (MAKE30: death, new renal replacement therapy, or persistent renal dysfunction).
Mechanism of Normal Saline Harm: Rapid, large-volume infusion of 0.9% NaCl (154 mEq/L Na +154 mEq/L Na + and 154 mEq/L Cl −154 mEq/L Cl −) induces hyperchloremic metabolic acidosis.
High chloride delivery to the macula densa of the nephron causes tubuloglomerular feedback, renal afferent arteriolar vasoconstriction, reduced glomerular filtration rate, and renal ischemia.
Formulary Rule: Use Balanced Crystalloids (COMPOUND SODIUM LACTATE) for high-volume resuscitation; reserve 0.9% NaCl for hypochloremia, hyponatremia, or neurotrauma.
First-Line Vasopressor (SOAP II)
First-Line Vasopressor: Norepinephrine vs. Dopamine The SOAP II Trial (De Backer et al., NEJM): In patients with septic shock, Dopamine was associated with a higher 28-day mortality in cardiogenic shock and significantly higher rates of arrhythmogenic events across all shock categories (24.1% in the dopamine group vs. 12.4% in the norepinephrine group; p<0.001).
Mechanism: Norepinephrine is a potent α1-adrenergic vasoconstrictor with modest β1 -inotropic activity.
It restores vascular tone in vasoplegic septic shock without the excessive chronotropic drive and arrhythmias seen with dopamine.
Norepinephrine is the mandatory first-choice vasopressor (Surviving Sepsis Campaign).
Antibiotic Timing
Empiric Broad-Spectrum Antimicrobial Timing: Every 1-hour delay in administering appropriate broad-spectrum antimicrobials in septic shock is associated with an incremental increase in mortality of approximately 7.6% (Kumar et al., Crit Care Med).
Antibiotics must be initiated within ≤1 hour of triage recognition.
In-ER Pharmacotherapy (Surviving Sepsis 1-Hour Bundle) — see steps below
1. Emergent Intravenous Crystalloid Resuscitation
Formulary Match: COMPOUND SODIUM LACTATE 500 ML 6 G (MSS) or RINGER LACTATE S.A.L.F 500 ML BOTTLE (Nobel Store).
Target Volume: 30 ml/kg IV administered within 3 hours, initiated immediately with the first 1000–2000 ml run under pressure over 30–60 minutes.
Assessment of Volume Responsiveness: Avoid static CVP goals.
Use dynamic parameters: Passive Leg Raise (PLR) challenge paired with real-time stroke volume measurement, bedside inferior vena cava (IVC) collapsibility index on ultrasound, clearing of serum lactate, and normalization of capillary refill time (≤2 seconds).
2. First-Line Vasopressor Infusion (For Persistent Hypotension During or Post-Fluid Resuscitation)
Preparation & Dilution: Dilute 4 mg (4 ml of 1 mg/ml solution) into 246 ml of DEXTROSE 5% ALISON IV INFUSION 250ML (Alison) (D5W prevents oxidation of norepinephrine) to yield a concentration of 16 mcg/ml.
Infusion Rate: Start at 0.05–0.1 mcg/kg/min via infusion pump.
Titrate rapidly every 2–5 minutes to achieve target MAP ≥65 mmHg MAP≥65 mmHg. (Can be run temporarily through a large, secure peripheral vein in the antecubital fossa while central venous access is being established).
Second-Line Vasopressor (Vasopressin Synergy)
Formulary Match: VASOPRESSIN FARMAK 20IU/ML 10 AMP (Al Bayan Drug Store).
Dose: Fixed continuous infusion of 0.03 units/min (do NOT titrate).
Vasopressin restores vascular reactivity in end-stage vasoplegia and reduces high norepinephrine requirements.
3. Broad-Spectrum Empiric Antimicrobials (Initiate within ≤1 hour)
Dose: 4.5 g IV stat loading dose, followed by 4.5 g IV every 6 hours (or 3.375 g q6h).
Alternative for Severe Intra-Abdominal Sepsis/High Extended-Spectrum β -Lactamase (ESBL) Prevalence/Severe Beta-Lactam Anaphylaxis: Formulary Match: MERO-AVENIR VIAL 1000MG (Beit Al-Dawaa) or J-PENEM 1gm VIAL (Jepharm) or MEROPENEM 1 G 10 VIAL (BPC).
Dose: 1000 mg (1 g) IV every 8 hours (administered as an extended infusion over 3 hours post-loading dose).
Formulary Match: VANCOAVENIR VIAL 1G 10/BOX (Beit Al-Dawaa) or VANCOMYCINE MYLAN 1G VIAL (Alram) or Vancomycin Hikma 500 MG.
Loading Dose: 25–30 mg/kg IV loading dose (actual body weight; max 2000–2500 mg).
Infusion Safety: Dilute to ≤5 mg/ml in SODIUM CHLORIDE 0.9% 500 ML and infuse at a rate not exceeding 10 mg/min (typically over 120 minutes) to prevent infusion-related anaphylactoid reactions.
Inpatient Critical Care Admission: Patients in septic shock require immediate admission to the Intensive Care Unit (ICU).
Outpatient management is contraindicated.
Red Flags & Safety Warnings • Fluid Overload (Rales/Gallop): • Repeated fluid boluses in non-fluid-responsive patients lead to pulmonary edema, intra-abdominal hypertension, and increased mortality. • Stop fluids when dynamic measures indicate fluid responsiveness is exhausted; use norepinephrine early to maintain diastolic coronary perfusion. • Lactate Clearance Monitoring: Serial venous/arterial lactate measurements should be obtained every 2 to 4 hours. • A failure of lactate to clear by ≥10–20% every 2 hours indicates persistent cellular dysoxia, under-resuscitation, or uncontrolled septic source requiring urgent operative intervention.
6. ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD) 1
Steroids 5 daysGOLD · REDUCE▾
6. ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD)
Duo-neb on air · Anthonisen antibiotics · 88–92% oxygen
Background talk — presentation, triage & evidence
Clinical Presentation & Diagnostic Triage Pathophysiology: Acute worsening of airflow limitation caused by bacterial or viral infection, pollutants, or environmental exposures.
Results in airway inflammation, mucosal edema, loss of elastic recoil, severe dynamic air-trapping (intrinsic PEEP), ventilation-perfusion mismatch, hypercapnia, and respiratory acidosis.
Triage (Anthonisen Criteria)
Diagnostic Triage (Anthonisen Criteria):
Type 1 (Severe)
All 3 cardinal symptoms present: worsening dyspnea, increased sputum volume, and increased sputum purulence (hallmark of bacterial infection).
Type 2 (Moderate)
Any 2 cardinal symptoms present.
Type 3 (Mild)
One cardinal symptom plus ≥1 of: sore throat, cough, fever, or wheeze.
ABG Thresholds
Arterial Blood Gas (ABG) Thresholds for Acute Respiratory Failure: pH <7.35 pH<7.35 and PaCO 2 >45 mmHg (>6.0 kPa) indicate acute decompensated hypercapnic respiratory failure requiring urgent Non-Invasive Ventilation (NIV/BiPAP).
Steroids — 5 Days (REDUCE)
Comparative Evidence & Pharmacological Rationale — Systemic Corticosteroids: 5 Days Oral vs. 14 Days Parenteral (The REDUCE Trial) The REDUCE Trial (Leuppi et al., JAMA): Evaluated oral prednisone 40 mg daily for 5 days versus the traditional 14-day regimen in patients presenting to the ER with AECOPD.
Findings: The 5-day short-course regimen was non-inferior to the 14-day course regarding the primary endpoint of time to next exacerbation over 6 months, with identical rates of in-hospital mortality, FEV1 recovery, and need for mechanical ventilation.
Formulary Rule: Administer a short 5-day steroid course (PREDNILET 20 MG or PREDNITAB 20 MG).
Prolonged courses increase the risk of steroid-induced hyperglycemia, secondary infections, and acute corticosteroid myopathy, which impairs diaphragmatic contractility and complicates weaning from ventilation.
Antibiotic Selection in AECOPD — When are Antibiotics Indicated (GOLD Guidelines): Antibiotics provide clear clinical benefit in patients with: All 3 Anthonisen cardinal symptoms (dyspnea, sputum volume, sputum purulence).
Increased sputum purulence plus one other cardinal symptom.
Exacerbation requiring mechanical ventilation (invasive or non-invasive).
Comparative Efficacy: Pathogens: Non-typeable H. influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis account for >80% of bacterial exacerbations.
First-Line Choice: High-dose Amoxicillin-Clavulanate (Augmentin 875mg, Ecoclav BID 1000) provides balanced bactericidal activity, including coverage against β -lactamase-producing H. influenzae and M. catarrhalis.
Fluoroquinolones: Moxifloxacin (MOXIFLOX 400 MG, BASILOX 400 mg) or Levofloxacin (LEVOX 500MG, TAVANIC 500 MG) should be reserved for patients with severe underlying airflow obstruction (FEV1 <50%), frequent exacerbations (≥2/year), or risk factors for Pseudomonas aeruginosa (bronchiectasis, chronic systemic steroid use).
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Administration: Combine 1.0 ml Salbutamol +2.0 ml 2.0 ml Ipratropium into the nebulizer chamber.
Nebulize using compressed room air, NOT high-flow oxygen, driving the gas flow at 6–8 L/min. Repeat every 20–30 minutes for 3 doses, then every 2–4 hours as needed.
2. Systemic Corticosteroids — Oral Administration (Preferred if Patient Can Swallow and is Alert)
Formulary Match: SAMIXON 1000 MG IV (Pharmacare Store) or CEFIXON 1G VIAL (BPC) (Scientific: Ceftriaxone 1 g).
Dose: 1000–2000 mg (1–2 g) IV once daily.
First-Line Oral Option
First-Line Oral Option: Formulary Match: Augmentin 875mg Tab. x 14 (GSK) or Ecoclav BID 1000 (875/125)- 14TAB (Pharmacare Store) or CLAMOXIN BID 875 (Jepharm).
Dose: 1 tablet (875/125 mg) PO twice daily with meals for 5 to 7 days.
Discharge & Outpatient Transition Regimen
Criteria for Discharge: Able to manage at home, dyspnea controlled, ambulatory (if baseline ambulatory), SpO2 stable between 88–92%, no respiratory acidosis on venous/arterial gas, inhaler technique reviewed.
Sig: Inhale 2 puffs twice daily (morning and evening); rinse mouth after use.
Red Flags & Safety Warnings • Controlled Oxygen Delivery (88–92% Target): Never place an AECOPD patient on unmonitored high-flow nasal cannula or a non-rebreather mask unless they are in cardiac arrest. • Supplying excess oxygen removes hypoxic vasoconstriction, increasing dead space ventilation (the Haldane effect), and suppresses hypoxic ventilatory drive, leading to acute hypercapnic coma and death. • Titrate supplemental oxygen via Venturi mask or low-flow nasal prongs (1–2 L/min) strictly targeting SpO2 between 88% and 92%. • Non-Invasive Positive Pressure Ventilation (BiPAP): • If arterial blood gas demonstrates acute respiratory acidosis (pH <7.35 pH<7.35, PaCO 2 >45 mmHg) despite initial nebulizers, initiate BiPAP immediately. • BiPAP reduces intubation rates by >60% and reduces mortality by >50% in acute hypercapnic respiratory failure.
Intravenous Proton Pump Inhibitors (PPIs) — Mechanism: Gastric pepsinogen is irreversibly inactivated only at pH >6.0 pH>6.0.
Maintaining an intragastric pH ≥6.0 pH≥6.0 stabilizes the platelet-fibrin plug over the arterial bleeding defect, halts fibrinolysis, and promotes clot organization.
Infusion vs. Intermittent Bolus
Continuous Infusion vs. Intermittent Bolus Dosing: Cochrane Systematic Review & Meta-Analyses (Sachar et al., JAMA): Compared the classic high-dose regimen (80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours) with intermittent dosing (40–80 mg IV push every 12 hours).
Finding: Intermittent IV PPI therapy is non-inferior to continuous infusion in terms of 30-day rebleeding rates (RR 0.92), surgical interventions, and all-cause mortality, while significantly lowering total drug expenditure and line maintenance burden.
Formulary Rule: In high-risk endoscopic stigmata (Forrest Ia/Ib spurting/oozing or IIa non-bleeding visible vessel post-hemostasis), continuous infusion or aggressive 80 mg BID bolus is endorsed for 72 hours.
Vasoactives — Terlipressin vs. Octreotide
Splanchnic Vasoactive Agents: Terlipressin vs. Octreotide (In Suspected Variceal Bleed)
Hemodynamic Action: Both agents induce selective splanchnic arterial vasoconstriction, decreasing mesenteric blood inflow into the portal venous system, rapidly lowering portal pressure (HVPG) and variceal wall tension.
Terlipressin Superiority: Terlipressin (GLYPRESSIN) is a synthetic vasopressin analogue that slowly cleaves into active lysine-vasopressin.
Cochrane reviews and landmark RCTs show that Terlipressin is the only vasoactive agent demonstrated to produce a statistically significant reduction in all-cause mortality in acute variceal bleeding compared to placebo (RR 0.66).
Octreotide Mechanism: Octreotide (Sandostatin) inhibits the postprandial release of vasodilatory peptides (such as glucagon and vasoactive intestinal peptide).
It lowers portal pressures with fewer systemic hypertensive and ischemic events than terlipressin, making it the safer alternative in patients with preexisting severe coronary artery disease, peripheral vascular disease, or mesenteric ischemia.
Antibiotics in Cirrhosis
Prophylactic Antimicrobial Therapy in Cirrhosis (Mandatory Intervention): Cirrhotic patients presenting with UGIB have an impaired reticuloendothelial system and high rates of bacterial translocation.
Up to 45% develop severe bacterial infections (spontaneous bacterial peritonitis, bacteremia, pneumonia) within 48 hours of presentation.
Evidence: Cochrane Systematic Reviews demonstrate that early intravenous prophylactic antibiotics reduce total bacterial infections, reduce early rebleeding rates by 50%, and significantly reduce all-cause in-hospital mortality (RR 0.79).
Intravenous Ceftriaxone (1 g/day) for up to 7 days is the guideline gold standard.
Formulary Match: SODIUM CHLORIDE 0.9% INTRAVENOUS INFUSION BP BAGS 500 ML (Teva) or COMPOUND SODIUM LACTATE 500 ML 6 G (MSS).
Run 500–1000 ml rapidly to correct orthostasis or shock.
Restrictive Transfusion Strategy (Villanueva et al., NEJM): Target hemoglobin is 7.0–8.0 g/dL (transfuse when Hb <7.0 g/dL Hb<7.0 g/dL).
Liberal transfusion (Hb <9.0 g/dL Hb<9.0 g/dL) elevates portal pressures, increases acute rebleeding, and raises mortality in both variceal and non-variceal bleeding (except in patients with active, severe acute myocardial ischemia, where target is Hb ≥8.0 g/dL Hb≥8.0 g/dL).
2. High-Dose Acid Suppression (Administer Stat for All Suspected UGIB)
Formulary Match: CONTROLOC 40 MG - VIAL (Grand Pharm) or PANTOPRAZOLE KALCEKS 40 MG - 10 VIAL (Medimarket) or NEXIUM 40MG - 10 VIAL (Omnipal) or Panto A venir 40 mg 20 vial/box (Beit Al-Dawaa) (Scientific: Pantoprazole or Esomeprazole 40 mg IV).
High-Dose Protocol: Step 1 (Loading Bolus): Administer 80 mg IV push (two 40 mg vials reconstituted with 10 ml 0.9% NaCl each, pushed over 5 minutes).
Step 2 (Continuous Maintenance Infusion)
Dilute 200 mg of Pantoprazole (five 40 mg vials) into 250 ml of SODIUM CHLORIDE 0.9% 250ML BOTTLE (Nobel Store) or DEXTROSE 5% ALISON IV INFUSION 250ML (Alison) (Concentration=0.8 mg/ml).
Infuse at 10 ml/hour (8 mg/hour) via dedicated infusion pump for 72 hours.
Alternative (Intermittent Bolus Protocol - Supported by Meta-Analyses): 80 mg IV bolus stat, followed by 80 mg IV push every 12 hours for 72 hours.
Dose: 10 mg IV slow push administered 30 to 60 minutes prior to endoscopy.
Evidence: Prokinetics promote gastric emptying of pooled blood and obstructive clots, improving visual field clarity during endoscopy and reducing the need for repeat endoscopic interventions.
Ringer 1.5 ml/kg/h · tramadol/fentanyl · tazo vs ceftriaxone+metro
Background talk — pancreas, biliary & antibiotics
Clinical Presentation & Diagnostic Triage — Acute Pancreatitis (Atlanta Classification — Any 2 of 3): Acute epigastric abdominal pain classically radiating to the mid-back.
Serum lipase or amylase ≥3 × ≥3× the upper limit of normal. Characteristic cross-sectional imaging features (edematous or necrotizing changes on CT/MRI/Ultrasound).
Secondary Peritonitis/Perforated Viscus: Sudden onset severe abdominal pain, board-like involuntary guarding, rebound tenderness, free intraperitoneal air on erect chest X-ray or CT.
Fluids — WATERFALL Trial
Comparative Evidence & Pharmacological Rationale Fluid Resuscitation in Pancreatitis: The WATERFALL Trial (de-Madaria et al., NEJM 2022): Early aggressive hydration (20 ml/kg bolus followed by 3 ml/kg/hour) versus moderate, goal-directed hydration (10 ml/kg bolus only if hypovolemic, followed by 1.5 ml/kg/hour) with Ringer's Lactate.
Findings: Aggressive hydration did not improve clinical outcomes; instead, it tripled the incidence of fluid overload (20.5% vs. 6.3%; adjusted RR 2.85), leading to respiratory failure and longer hospitalizations.
Fluid Selection: Ringer's Lactate (COMPOUND SODIUM LACTATE) is superior to Normal Saline (0.9% NaCl); saline worsens metabolic acidosis and promotes pancreatic acinar enzyme activation via localized acidosis.
No Prophylactic Antibiotics
Prophylactic Antibiotics in Acute Pancreatitis: Cochrane Consensus — Do NOT Give Prophylactic Antibiotics in Mild or Non-Infected Pancreatitis: Multiple double-blind placebo-controlled RCTs and Cochrane reviews demonstrate that routine empiric prophylactic antibiotics in necrotizing or interstitial edematous pancreatitis do not decrease mortality, prevent infected necrosis, or reduce the need for surgery.
Prophylactic overuse selects for multidrug-resistant pathogens and fungal peritonitis.
When Antibiotics ARE Indicated: Administer targeted antimicrobials for clear evidence of infection: infected pancreatic necrosis (gas on CT or positive fine-needle aspirate), ascending cholangitis, bacteremia, or acute secondary peritonitis from perforation.
Empiric Regimens
Antimicrobial Selection for Intra-Abdominal Sepsis: Pathogens are typically polymicrobial: Gram-negative enterics (Escherichia coli, Klebsiella pneumoniae, Proteus) and enteric anaerobes (Bacteroides fragilis).
Monotherapy: Piperacillin-Tazobactam (TAZO-PIP AVENIR) covers enterics, Pseudomonas, enterococci, and Bacteroides.
Combination Therapy: Ceftriaxone (SAMIXON) or Ciprofloxacin (CIPROFLOXACIN I.V ALTAN) plus Metronidazole (METRONIDAZOLE B.BRAUN) provides comprehensive coverage against colonic enterics and anaerobes.
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Formulary Match: COMPOUND SODIUM LACTATE 500 ML 6 G (MSS) or RINGER LACTATE S.A.L.F 500 ML BOTTLE (Nobel Store).
Protocol: If Euvolemic (Normal BP, Normal HR, Normal Skin Turgor): No bolus.
Initiate maintenance infusion at 1.5 ml/kg/hour (100–125 ml/hr for a 70 kg adult).
If Hypovolemic (Tachycardia, Hypotension, Elevated BUN/Hematocrit): Administer a cautious single bolus of 10 ml/kg IV over 2 hours, followed by maintenance at 1.5 ml/kg/hour.
Reassessment: Re-evaluate clinical markers every 12 hours.
Dose: 50–100 mg IV slow push over 5–10 minutes every 6 hours as needed (Max 400 mg/day).
Alternative for Severe/Agonizing Pain: FENTANYL KALCEKS 0.05MG/ML (2ML) (Medimarket): 25–50 mcg IV slow push every 30–60 minutes; OR MORPHINE KALCEKS 10MG - 10AMP (Medimarket): 2–4 mg IV push every 2–4 hours. (Sphincter of Oddi Myth: Rigorous human trials confirm clinical morphine does not induce clinically significant sphincter of Oddi spasm that alters pancreatitis outcomes; it is safe when titrated carefully).
Red Flags & Safety Warnings • Avoid Empiric Ceftriaxone in • Ascending Cholangitis if Prior Biliary Stenting: Patients with previous biliary manipulation, plastic stents, or sphincterotomies are frequently colonized with enterococci, Pseudomonas, or multidrug-resistant pathogens; use Piperacillin-Tazobactam or Meropenem instead of Ceftriaxone. • Ketorolac/NSAID Danger in Pancreatitis: Avoid NSAIDs in the acute resuscitation phase of acute pancreatitis. • Pancreatitis patients are intravascularly depleted due to capillary leak; blocking renal prostaglandins can trigger acute tubular necrosis and sudden anuric renal failure.
Clinical Presentation & Diagnostic Triage Pathophysiology: Thrombotic or embolic occlusion of a cerebral artery leading to focal hypoperfusion.
The Core: Brain tissue with cerebral blood flow <10 ml/100 g/min, undergoing irreversible cellular necrosis within minutes.
The Penumbra: Surrounding zone of critically hypoperfused but biochemically viable brain tissue (10–20 ml/100 g/min), salvageable if perfusion is restored rapidly.
Emergency Metrics: Door-to-CT Time: Non-contrast brain CT within ≤20 minutes of arrival to rule out intracranial hemorrhage (ICH).
ABCD 2 Score for TIA: Age ≥60 (1 pt), BP ≥140/90 (1 pt), Clinical features (unilateral weakness=2 pts, speech disturbance without weakness=1 pt), Duration (≥60 min=2 pts, 10–59 min=1 pt), Diabetes (1 pt).
A score ≥4 defines high-risk TIA, which carries up to an 8–10% risk of stroke within 48 hours.
DAPT — POINT & CHANCE
Comparative Evidence & Pharmacological Rationale — Early Dual Antiplatelet Therapy (DAPT): The POINT and CHANCE Trials The CHANCE Trial (Wang et al., NEJM) & The POINT Trial (Johnston et al., NEJM): Evaluated early DAPT (Clopidogrel + Aspirin) versus Aspirin monotherapy initiated within 12–24 hours of symptom onset in patients with minor acute ischemic stroke (NIHSS ≤3 NIHSS≤3) or high-risk TIA (ABCD 2 ≥4).
Findings: DAPT significantly reduced the risk of major ischemic stroke at 90 days compared to aspirin alone (5.0% vs. 6.5%; HR 0.75,95% CI 0.59–0.95; p=0.02).
The 21-Day Duration Rule: The clinical benefit of DAPT is concentrated within the first 21 days post-event.
Continuing DAPT beyond 21–30 days does not further reduce ischemic stroke risk, but significantly increases the risk of major hemorrhage (HR 2.32).
Formulary Rule: DAPT (Aspirin 100 mg + Clopidogrel 75 mg) is given for exactly 21 days, followed by monotherapy (Clopidogrel 75 mg daily or Aspirin 100 mg daily) indefinitely.
Permissive Hypertension (AHA/ASA)
Permissive Hypertension Management: When and How Much to Lower BP AHA/ASA Guidelines: In patients presenting with acute ischemic stroke who are not candidates for IV thrombolysis/endovascular thrombectomy (EVT), blood pressure should not be treated unless it exceeds: Systolic BP >220 mmHg or Diastolic BP >120 mmHg Systolic BP>220 mmHg or Diastolic BP>120 mmHg
Rationale: Perfusion to the ischemic penumbra depends on systemic arterial pressure.
Lowering BP reduces collateral blood flow, turning viable penumbra into irreversible infarction.
If BP >220/120 mmHg BP>220/120 mmHg, lower MAP cautiously by 15% over the first 24 hours.
If Thrombolysis (Alteplase) is Planned
BP must be brought to and maintained at SBP <185 mmHg SBP<185 mmHg and DBP <110 mmHg DBP<110 mmHg prior to thrombolysis, and held below 180/105 mmHg for 24 hours post-thrombolysis to prevent fatal hemorrhagic transformation.
If target is not reached, repeat 20–40 mg every 10 minutes (max 300 mg).
Target a 15% reduction in MAP; do not normalize aggressively.
Scenario B — Thrombolysis Candidate with BP >185/110 mmHg
Administer LABETALOL AMP 5MG/ML: 10–20 mg IV push.
Repeat once if necessary.
If BP does not drop below 185/110 mmHg, thrombolysis is contraindicated due to intracerebral hemorrhage risk.
2. Emergent DAPT
Loading (Post-CT Confirmation — ICH Excluded): Only initiate after non-contrast CT head definitively rules out intracranial hemorrhage and thrombolysis is NOT indicated.
Formulary Match: CLEXANE 40MG SAFETY LOCK PREFIL SYR (MSS) or ENOXAPARIN LEDRAXEN 4000 IU (40MG)/0.4ML (True med).
Dose: 40 mg (0.4 ml) Subcutaneously once daily.
Rule: Withhold for the first 24 hours post-thrombolysis; if no thrombolytic was administered, initiate within 24–48 hours in immobile patients after stable repeat neuroimaging.
Discharge & Outpatient Transition Regimen (Minor Stroke NIHSS ≤3 NIHSS≤3 or TIA ABCD 2 ≥4)
Red Flags & Safety Warnings • Hypoglycemia Screen: Hypoglycemia can mimic acute middle cerebral artery or basilar stroke syndromes. • Check capillary blood glucose immediately on arrival. If <60 mg/dL (<3.3 mmol/L<3.3 mmol/L), administer 50 ml of 10% Dextrose (DEXTROSE 10% ALISON IV INFUSION 500ML) and reassess focal deficits. • Do NOT Administer Anticoagulation in Acute Stroke: Unfractionated heparin and therapeutic-dose LMWH (CLEXANE 1mg/kg) are contraindicated in the acute phase of ischemic stroke, regardless of whether atrial fibrillation is present. • They do not improve ischemic outcomes and substantially increase the risk of fatal hemorrhagic transformation. • Defer therapeutic anticoagulation for 3 to 14 days based on infarct volume size.
Ketorolac + metoclopramide + dexamethasone · triptans vs QULIPTA
Background talk — status migrainosus & cocktail evidence
Clinical Presentation & Diagnostic Triage — Status Migrainosus Definition (ICHD-3): A debilitating migraine attack lasting >72 hours continuously, refractory to initial simple analgesics or triptans.
Pathophysiology: Trigeminovascular system activation triggering cortical spreading depression, antidromic release of vasoactive neuropeptides (Calcitonin Gene-Related Peptide [CGRP], Substance P, Neurokinin A), and sterile perivascular neurogenic inflammation.
Central Sensitization: If untreated, second- and third-order neurons within the trigeminocervical complex become sensitized, causing cutaneous allodynia (pain triggered by non-noxious stimuli like brushing hair or light touch), at which stage oral triptans lose clinical effectiveness.
Comparative Evidence & Pharmacological Rationale — The Multi-Modal ER "Migraine Cocktail"
Why Monotherapy Fails
Strategy — Why Single-Agent Treatment Fails: Severe refractory migraines involve both peripheral trigeminovascular activation and central dopamine receptor hypersensitivity.
Monotherapy (e.g., simple oral NSAIDs or opioids) is associated with high ER recurrence rates (>50%).
Metoclopramide vs. Opioids
Dopamine Receptor Antagonists (Metoclopramide) vs. Opioids: Friedman et al., Neurology: Compared IV Metoclopramide to IV opioids (hydromorphone, meperidine).
Metoclopramide was superior in headache relief at 2 hours and produced significantly lower rates of return to the ER.
Action: Metoclopramide targets central D2-dopamine receptors in the chemoreceptor trigger zone and nucleus tractus solitarius, relieving nausea, while simultaneously acting as a central neuromodulator of trigeminovascular pathways.
Parenteral NSAIDs (Ketorolac)
Inhibits meningeal prostaglandin synthesis.
Randomized double-blind trials demonstrate that IV Ketorolac (30 mg) is equivalent or superior to narcotics without inducing opioid receptor tolerance, sedation, or rebound medication-overuse headache.
Systemic Glucocorticoids (Dexamethasone)
Cochrane Systematic Review (Colman et al., BMJ): Adding a single dose of parenteral dexamethasone (8–16 mg) to acute migraine therapy reduces the rate of migraine recurrence within 72 hours by 30% (RR 0.71,95% CI 0.59–0.86; NNT=9).
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Formulary Match: DEXA-ALISON 8 MG/2 ML 5 AMP (Alison) or dexamethasone kalceks 8mg/2 ml (Medimarket) (Scientific: Dexamethasone Sodium Phosphate).
Dose: 8–10 mg IV push once.
Suppresses sustained neurogenic meningeal inflammation and prevents return to the ER within 72 hours.
Discharge & Outpatient Transition Regimen
Criteria for Discharge: Headache visual analog score (VAS) reduced by ≥70%, nausea resolved, able to tolerate oral fluids and medications, photophobia/phonophobia resolved.
Regimen A — Abortive Therapy
Regimen A — Acute Abortive Attack Therapy (For Next Inception of Headache): Educate patient: Take at the earliest warning sign of migraine, NOT when pain reaches maximum intensity.
Advantage: Does not induce arterial vasoconstriction; safe in patients with ischemic heart disease, coronary stents, or stroke, in whom Triptans are strictly contraindicated.
Red Flags & Safety Warnings • Opioid Prohibition in Migraine: Do not administer opioids (TRAMAL, MORPHINE KALCEKS, PERCOCET, COD ACAMOL) for migraine. • Opioids cause central sensitization, induce medication-overuse headache (rebound), decrease response to triptans, and carry high addiction liability. • Triptan Vascular Contraindications: Triptans are potent agonists at vascular 5-HT1B 5-HT1B receptors, mediating coronary, cerebral, and mesenteric arterial vasoconstriction. • Strictly contraindicated in: Coronary artery disease (prior MI, angina), peripheral vascular disease, history of stroke/TIA, uncontrolled hypertension, or hemiplegic/basilar migraine. • Use Atogepant (QULIPTA) or Ketorolac instead.
Acute Colic Mechanism: Proximal ureteral smooth muscle hyperperistalsis coupled with localized mucosal edema and release of vasodilatory prostaglandins (PGE2, PGI2).
Renal Dynamic Changes: PGE2 causes afferent arteriolar vasodilation, increasing glomerular filtration rate and intratubular pressures into a closed, obstructed system, resulting in severe renal capsular distension and visceral pain transmitted via T10–L1 dermatomes.
Imaging: Low-dose non-contrast CT of kidneys, ureters, and bladder (CT KUB) is the definitive modality (>98% sensitivity/specificity).
Measure stone diameter in millimeters and evaluate for hydronephrosis.
This induces afferent arteriolar vasoconstriction, lowering renal pelvic pressure and capsular stretch, while directly decreasing ureteral smooth muscle hyperactivity.
Opioid Limitations: Opioids (Morphine, Tramadol) only blunt central pain perception without treating renal capsular stretch.
They also increase nausea, cause sedation, and decrease ureteral peristalsis.
Systematic Review Evidence (Pathan et al., Cochrane Database & BMJ): NSAIDs achieve greater pain reduction at 30 minutes, have a longer duration of action, require significantly less rescue analgesia, and produce significantly lower rates of vomiting and adverse events compared to opioids.
Medical Expulsive Therapy (MET)
Alpha-1 Blockers (Tamsulosin) Mechanism: Ureteral smooth muscle contains a high density of post-synaptic α1D - and α1A-adrenergic receptors, primarily clustered in the distal ureter.
Antagonizing these receptors decreases basal ureteral tone, suppresses hyperperistalsis without abolishing normal bolus propagation, and lowers intraureteral pressure, facilitating stone passage.
Evidence from the SUSPENS Trial and Meta-Analyses: While MET has marginal benefit in small stones (<4–5 mm, which pass spontaneously >85% of the time), Tamsulosin (0.4 mg daily) significantly increases spontaneous stone clearance, reduces time to expulsion (by ≈4–6 days), and reduces analgesic requirements for distal ureteral stones between 5 mm and 10 mm (RR 1.45,95% CI 1.22–1.72).
Dose: 30 mg IV push over 1 minute (Reduce to 15 mg IV if age ≥65, weight <50 kg, or mild renal impairment).
Onset: Relief begins within 10 to 15 minutes; duration lasts 6 to 8 hours.
Option B — Diclofenac
Option B: Intramuscular Diclofenac:
Formulary Match: Diclo-Alison 75mg/3ml (Alison) or RUFENAL 3 ML AMP (BPC) (Scientific: Diclofenac Sodium 75 mg/3 ml).
Dose: 75 mg deep intramuscular injection into the gluteal muscle.
2. Rescue Analgesia for Refractory Pain/Contraindication to NSAIDs — Indicated if pain persists 30 minutes after NSAID, or if NSAIDs are contraindicated (active renal impairment with eGFR <30 eGFR<30, acute solitary kidney obstruction, pregnancy, or active peptic ulcer):
Discharge Criteria: Pain controlled with oral agents, stone <10 mm on CT without infection, normal renal function, no intractable vomiting, normal fluid intake.
1. Medical Expulsive Therapy (Distal Ureteral Stones 5 mm to 10 mm):
Scientific: Tramadol HCl 50 mg. Sig: Dissolve 1 to 2 tablets in a half glass of water and drink every 6 to 8 hours ONLY for severe breakthrough colic uncontrolled by Diclofenac/Ketorolac.
Red Flags & Safety Warnings • The Obstructed Infected Kidney (Urological Emergency): • Renal colic occurring with fever (>38°C>38°C), rigors, systemic inflammatory response, or pyuria on urinalysis indicates infected hydronephrosis/pyonephrosis. • Antibiotics cannot adequately penetrate an obstructed, pressurized collecting system. • Immediate emergent decompression via percutaneous nephrostomy (PCN) or retrograde ureteral double-J stenting is mandatory. • Defer MET; start empiric IV Ceftriaxone or Piperacillin-Tazobactam immediately. • Renal Function & Single Kidneys: NSAIDs are contraindicated in solitary functioning kidneys with acute obstruction, baseline eGFR <30 ml/min eGFR<30 ml/min, or renal transplants due to the risk of triggering uncompensated ischemic renal failure. • Rely on IV Paracetamol, Tramadol, or Morphine in these populations.
Diabetic Ketoacidosis (DKA): Absolute or profound relative insulin deficiency coupled with counter-regulatory hormone excess (glucagon, epinephrine, cortisol, growth hormone).
This triggers unrestrained lipolysis, liberating free fatty acids that undergo hepatic β-oxidation into ketoacids (β -hydroxybutyrate and acetoacetate), resulting in high anion gap metabolic acidosis, osmotic diuresis, total-body electrolyte depletion, and dehydration.
Hyperosmolar Hyperglycemic State (HHS)
Relative insulin deficiency sufficient to prevent lipolysis and ketogenesis, but inadequate to stimulate peripheral glucose uptake.
Extreme hyperglycemia leads to massive osmotic diuresis, profound total-body water deficit (100–200 ml/kg or 8–12 L), hyperosmolality (>320 mOsm/kg), and altered consciousness.
Diagnostic Criteria (ADA Consensus Guidelines)
Parameter Mild DKA Moderate DKA Severe DKA Hyperosmolar Hyperglycemic State (HHS) Plasma Glucose (mg/dL) >250 >600 Arterial/Venous pH 7.25–7.30 7.00–7.24 <7.00 >7.30 Serum Bicarbonate (mEq/L) 15–18 10–14 <10 >18 Urine/Serum Ketones Positive Absent to trace Effective Serum Osmolality Variable >320 mOsm/kg Anion Gap >10 >12 Variable (typically normal) Mental Status Alert Alert/Drowsy Stupor/Coma Anion Gap=Na + − (Cl − + HCO3 −) [Normal: 8–12 mEq/L] Anion Gap=Na + −(Cl − +HCO3 −)[Normal: 8–12 mEq/L] Effective Osmolality=2 × Na + (mEq/L)+ Glucose (mg/dL) 18 [Normal: 275–295 mOsm/kg] Effective Osmolality=2×Na + (mEq/L)+18 Glucose (mg/dL) [Normal: 275–295 mOsm/kg] Corrected Na +=Measured Na + +1.6 × [Glucose −100 100] (or 2.0 if glucose >400 mg/dL) Corrected Na +=Measured Na + +1.6×[100 Glucose−100](or 2.0 if glucose >400 mg/dL) Comparative Evidence & Pharmacological Rationale Resuscitation Fluids: Balanced Crystalloids vs. 0.9% Normal Saline (The SCOPE-DKA & BaSICS Trials)
Saline vs. Balanced (SCOPE-DKA)
Hyperchloremic Acidosis with Normal Saline: Administering large volumes of 0.9% NaCl (154 mEq/L Cl −154 mEq/L Cl −) causes hyperchloremia.
Excess chloride displaces bicarbonate in the plasma and triggers renal afferent arteriolar vasoconstriction, lowering GFR.
Trial Findings (Self et al., SCOPE-DKA, Am J Respir Crit Care Med): Resuscitation with balanced crystalloids (Ringer's Lactate; COMPOUND SODIUM LACTATE) led to significantly faster resolution of DKA (median 13.0 hours vs. 16.9 hours) and accelerated normalization of serum bicarbonate compared with 0.9% NaCl.
Formulary Rule: Initiate volume expansion with Balanced Crystalloids (COMPOUND SODIUM LACTATE) or 0.9% NaCl for the first 1–2 liters; transition to 0.45% NaCl (SODIUM CHLORIDE 0.45%) if corrected sodium is normal or elevated.
Potassium First
The Potassium-First Rule (Preventing Fatal Arrhythmias): Insulin drives potassium into cells via the Na+/K+-ATPase pump, and rehydration dilutes extracellular potassium.
If insulin is administered when serum potassium is low, rapid shifts can cause severe hypokalemia, diaphragmatic paralysis, QT prolongation, ventricular fibrillation, or asystole.
Mandatory Algorithm: If K + <3.3 mEq/L: Hold insulin completely.
Infuse IV potassium until K + >3.3 mEq/L.
If K +=3.3–5.2 mEq/L: Administer insulin and add 20–30 mEq potassium per liter of IV fluid.
If K + >5.2 mEq/L: Initiate insulin; withhold potassium replacement, but check levels every 2 hours.
Insulin Infusion (No Bolus)
Continuous Low-Dose Infusion vs. IV Bolus Insulin: An initial IV insulin bolus (0.1 U/kg) offers no clinical advantage over starting a continuous fixed infusion of 0.1 U/kg/hour, and increases the risk of precipitous hypokalemia and hypoglycemia without accelerating ketoacidosis resolution.
Target Descent Rate: Plasma glucose should fall at a controlled rate of 50–75 mg/dL/hour.
If glucose falls too fast (>100 mg/dL/hour), the rapid reduction in plasma osmolality creates an osmotic gradient that drives water into brain parenchyma, triggering cerebral edema.
Bicarbonate — Restricted (BICAR-ICU)
The Bicarbonate Controversy in DKA — Systematic Reviews & The BICAR-ICU Trial: Routine sodium bicarbonate administration in DKA with pH ≥6.9 pH≥6.9 does not improve morbidity or mortality.
Mechanisms of Bicarbonate Harm: Paradoxical Intracellular/CSF Acidosis: Bicarbonate combines with hydrogen ions to form H2CO3, which dissociates into H2O and CO2.
Lipophilic CO2 freely diffuses across the blood-brain barrier faster than charged HCO3 −, worsening central nervous system acidosis.
Hypokalemia: Shifts more potassium intracellularly.
Impaired Oxygen Delivery: Shifts the oxyhemoglobin dissociation curve to the left (Bohr effect), decreasing tissue oxygen unloading.
Delayed Ketone Clearance: Hepatic ketogenesis is prolonged by alkalization.
Guideline Exception: Reserve sodium bicarbonate exclusively for life-threatening acidemia with pH <6.90 pH<6.90 associated with hemodynamic instability.
Preparation of Infusion Solution: Draw 50 units (0.5 ml) of INSU.ACTRAPID using an insulin syringe.
Inject into a 50 ml bag of SODIUM CHLORIDE 0.9% (or 100 units into 100 ml).
Final Concentration: 1 Unit/1 ml.
Line Priming: Flush 20 ml of the solution through the IV tubing and discard before connecting to the patient (saturates plastic binding sites on polyvinyl chloride tubing).
Dosing & Infusion Rate: Initiate continuous infusion at 0.1 Units/kg/hour via dedicated infusion pump. (e.g., 70 kg adult=7 Units/hour=7 ml/hour of 1 U/ml solution).
Rate Titration Targets: Target a steady decrease in blood glucose of 50–75 mg/dL/hour.
If glucose does not fall by at least 50 mg/dL in the first hour, double the insulin infusion rate (e.g., increase to 0.2 U/kg/hour) and verify IV patency.
Phase 4 — Glucose Add-Back
Phase 4: The Glycemic Transition (The Two-Bag/Glucose Add-Back Phase) — When Blood Glucose Reaches 200 mg/dL (in DKA) or 300 mg/dL (in HHS): Do NOT stop the insulin infusion.
Ketoacidosis resolution requires continued insulin to suppress lipolysis and clear ketones.
Add dextrose to the IV fluids: Formulary Match: SODIUM CHLORIDE 0.9% & DEXTROSE 5% ALISON IV INFUSION-12*500ML (Alison) (Scientific: 5% Dextrose with 0.9% NaCl) OR DEXTROSE 10% ALISON IV INFUSION 500ML (Alison).
Reduce the insulin infusion rate to 0.02–0.05 Units/kg/hour.
Titrate the dextrose infusion and insulin to maintain blood glucose between 150–200 mg/dL until the ketoacidosis is fully resolved.
Phase 5 — Bicarbonate (pH<6.9 Only)
Phase 5: Emergency Bicarbonate Therapy (Restricted to pH <6.90 pH<6.90)
Dose: 100 mmol (100 ml) mixed into 400 ml of sterile water or 0.45% NaCl, infused with 20 mEq KCl over 2 hours.
Repeat every 2 hours until venous pH ≥7.00 pH≥7.00.
Inpatient Transition
Inpatient Stabilization & Transition to Subcutaneous Insulin — Criteria for DKA Resolution: Blood glucose <200 mg/dL AND any two of: Serum venous pH >7.30 pH>7.30, Serum Bicarbonate ≥18 mEq/L≥18 mEq/L, Normal Anion Gap (≤12 mEq/L≤12 mEq/L).
Patient must be alert and tolerating an oral diet.
The Overlap Rule: Administer basal subcutaneous insulin 2 hours before stopping the IV insulin infusion.
Discontinuing the IV insulin drip without prior subcutaneous basal insulin leads to rapid rebound ketoacidosis within 30–60 minutes (regular IV insulin has an elimination half-life of only 4–5 minutes).
1. Long-Acting Basal Insulin (Administer 2 hours prior to stopping IV drip):
Sig: Inject [Calculate: 0.05–0.1 Units/kg] Subcutaneously immediately before meals (TID).
Example: 5 to 6 Units SC 0–10 minutes before Breakfast, Lunch, and Dinner.*
3. Outpatient Glucose Management & Glycemic Rescue: Self-monitoring of blood glucose (SMBG) — QID (fasting and 2-hour postprandial).
Follow-up in Endocrinology/Diabetes clinic within 5–7 days.
Red Flags & Safety Warnings • Cerebral Edema in DKA: More common in pediatric and young adult patients. • Warning signs include headache, lethargy, bradycardia and hypertension (Cushing's triad), and cranial nerve palsies. • If cerebral edema is suspected: Immediately administer 20% • Mannitol: MANNITOL 20% IMUNA SOLUTION FOR INFUSION 500 ML (Al-Nasr) at 0.5–1.0 g/kg IV over 20 minutes; OR Hypertonic Saline (3%); elevate head of bed to 30 ∘ 30 ∘, and reduce fluid administration rates. • Euglycemic DKA (euDKA) Induced by SGLT2 Inhibitors: • Patients taking oral SGLT2 inhibitors (FORXIGA, EMPA-10, STEGLATRO) can develop severe ketoacidosis with near-normal blood glucose levels (<200–250 mg/dL). • Always check an arterial/venous blood gas and urine/serum ketones in any unwell patient on an SGLT2 inhibitor, regardless of blood glucose level. • Discontinue SGLT2 inhibitors immediately and treat with IV fluids and glucose-supported IV insulin infusions.
Clinical Presentation & Diagnostic Triage Pathophysiology: Elevated extracellular potassium disrupts the resting membrane potential (V m) of cardiac myocytes via the Nernst relationship: V m ≈ −61.5 log ([K +] in [K +] out) V m ≈−61.5log([K +] out [K +] in) Hyperkalemia partially depolarizes the myocyte resting potential (makes it less negative), causing initial hyperexcitability, followed by fast sodium channel inactivation, which slows phase 0 myocardial depolarization and impairs intraventricular conduction.
ECG Progression
ECG Progression of Hyperkalemic Cardiotoxicity: Early (K + ≈5.5–6.5 mEq/L): Narrow, peaked, symmetrical T waves with a shortened QT interval (accelerated phase 3 repolarization).
Moderate (K + ≈6.5–7.5 mEq/L): Prolongation of the PR interval, flattening/loss of P waves, depression of ST segments.
Severe/Life-Threatening (K + >7.5–8.0 mEq/L): Progressive widening of the QRS complex, blending with the T wave to produce a classical sine wave pattern.
Terminal: Ventricular fibrillation, pulseless electrical activity (PEA), or asystole.
Clinical Rule: Any ECG change attributable to hyperkalemia represents a medical emergency requiring immediate intravenous membrane stabilization.
Three Pillars
Comparative Evidence & Pharmacological Rationale — The Three-Pillar Therapeutic Strategy: Phase 1: Myocardial Membrane Stabilization (Immediate onset, 1–3 minutes; zero effect on serum potassium).
Phase 2: Intracellular Potassium Shifting (Intermediate onset, 15–30 minutes; drives potassium from extracellular to intracellular space).
Phase 3: Total-Body Potassium Elimination (Delayed onset, 1–4 hours; removes potassium from the body).
Calcium Gluconate vs. Calcium Chloride — Selection & Toxicity: Electrophysiologic Action: Extracellular calcium does not lower serum potassium.
It increases the threshold potential (V th), restoring the normal difference between resting membrane potential and threshold potential, which reverses cardiac conduction block and normalizes QRS duration within minutes.
Formulation Rationale: CALCIUM GLUCONATE 10%: Preferred in peripheral IV lines.
A 10 ml ampoule contains 4.6 mEq of elemental calcium (93 mg).
It has low osmolarity and rarely causes severe tissue necrosis if extravasation occurs.
Calcium Chloride 10% contains 3×3× more elemental calcium (13.6 mEq per 10 ml), but carries a high risk of chemical thrombophlebitis and severe ischemic soft-tissue necrosis on extravasation; it is reserved for central venous access or active cardiac arrest.
Shifting — Insulin vs. Salbutamol
Intracellular Shifting — Insulin + Dextrose vs. Nebulized Salbutamol — Regular Insulin: Binds β -subunits of the insulin receptor on skeletal muscle and hepatocytes, activating the Na+/K+-ATPase pump and translocating potassium into cells.
A dose of 10 Units IV combined with dextrose reliably lowers serum potassium by 0.6–1.0 mEq/L within 30 to 60 minutes, with effects lasting 4 to 6 hours.
Nebulized Salbutamol: Stimulates β2-adrenergic receptors linked to adenylate cyclase, increasing cAMP and activating the Na+/K+-ATPase pump.
High-Dose Requirement: Standard asthma doses (2.5–5 mg) do not reliably shift potassium.
A high dose of 10–20 mg nebulized is required, which lowers potassium by an additional 0.5–1.0 mEq/L.
Additive Synergy: Combining insulin-dextrose with high-dose nebulized salbutamol provides greater potassium reduction than either agent alone, while salbutamol's glycogenolytic activity helps protect against insulin-induced hypoglycemia.
Binders — SPS vs. Patiromer
Potassium Binders: Sodium Polystyrene Sulfonate (SPS) vs. Patiromer
Sodium Polystyrene Sulfonate (Kayexalate): Cation-exchange resin exchanging sodium for potassium in the distal colon.
Safety Concern: When formulated with high-concentration sorbitol, SPS is linked to intestinal necrosis, bowel perforation, and ischemic colitis (FDA black-box warning).
It should not be used with oral sorbitol.
Patiromer (Veltassa):
Non-absorbed calcium-sorbitol counter-ion spherical polymer that binds potassium in the gastrointestinal tract (predominantly the colon) in exchange for calcium.
Evidence (OPAL-HK & AMETHYST-DN Trials)
Patiromer lowers potassium safely without releasing large sodium loads, avoiding fluid overload in patients with congestive heart failure and end-stage renal disease (ESRD).
EMERGENCY HYPERKALEMIA PROTOCOL ECG Shows: Peaked T Waves/Broad QRS/Sine Wave/K+ >6.5 │ ▼ ┌─────────────────────────────────────────────────────────┐ │ STEP 1: MEMBRANE STABILIZATION (Time: 0 - 3 minutes) │ │ CALCIUM GLUCONATE 10%: 10 ml IV over 2 to 5 minutes │ │ (Normalizes QRS/ECG within 3 min; repeat once if no │ │ change at 5 min. Re-dosing needed after 30-60 min.) │ └────────────────────────────┬────────────────────────────┘ │ ▼ ┌─────────────────────────────────────────────────────────┐ │ STEP 2: INTRACELLULAR SHIFT (Time: 15 - 30 minutes) │ │ │ │ A) INSULIN + DEXTROSE: │ │ INSU.ACTRAPID: 10 Units IV bolus │ │ PLUS DEXTROSE 10%: 500 ml IV infusion over 30 min │ │ (Provides 50 g glucose; check POC glucose at 30, │ │ 60,90,120 min to catch late hypoglycemia) │ │ │ │ B)
DEXTROSE 10% ALISON IV INFUSION 500ML (Alison) (Scientific: 10% Dextrose Infusion=50 g glucose per 500 ml=50 g glucose per 500 ml).
Administration: Inject 10 Units of INSU.ACTRAPID IV push.
Immediately begin infusion of 500 ml of DEXTROSE 10% over 30 to 60 minutes (delivers 50 g dextrose, which counteracts 10 units of insulin and reduces hypoglycemia risk compared to bolus 50% dextrose).
Baseline Hyperglycemia Note: If initial blood glucose is >250 mg/dL, administer the 10 Units of Actrapid insulin alone without dextrose; monitor blood glucose every 30 minutes.
Nebulized Salbutamol
Formulary Match: VENTOLIN RESP.SOL. 5MG/MLX20ML (GSK) or VENTOL RESP. SOL (BPC) (Scientific: Salbutamol 5 mg/ml).
Dose: 10–20 mg (2.0–4.0 ml of solution) diluted with 2 ml 0.9% NaCl, nebulized continuously over 15 minutes driven by 6–8 L/min oxygen.
Criteria for Discharge: Serial serum K + <5.0 mEq/L measured 4 hours after last intervention, ECG fully normalized, underlying cause identified and addressed:
Sig: Take 1 sachet (8.4 g) by mouth once daily with water, separated from other oral medications by at least 3 hours (to prevent binding interactions).
Evidence (AMETHYST-DN Trial)
Maintains normokalemia in CKD/HF patients, allowing continuation of guideline-directed RAAS inhibitors (ACEi/ARB/MRA).
Red Flags & Safety Warnings • Hypoglycemia Post-Insulin/Dextrose: Up to 20–75% of hyperkalemic patients treated with IV insulin-dextrose develop iatrogenic hypoglycemia, typically peaking at 60 to 90 minutes post-administration, especially in patients with renal impairment (reduced renal insulin clearance). • Mandatory protocol: Check point-of-care capillary glucose at 30,60,90,120,180, and 240 minutes post-insulin. • Extravasation of Calcium: Calcium salts, particularly calcium chloride, can cause extensive full-thickness ischemic tissue necrosis and calcinosis cutis if extravasation occurs. • Confirm IV patency before injection, use a large vein, aspirate blood to confirm intravascular position, and flush with 20 ml normal saline post-infusion.
Prompt resolution of symptoms following glucose elevation.
Sulfonylurea Poisoning
Special Risk Category — Sulfonylurea Poisoning: Accidental ingestion, supratherapeutic dosing, or renal failure in patients taking long-acting sulfonylureas (AMARYL [Glimepiride], GLUBEN [Glibenclamide], GLUCORITE [Glipizide]).
Mechanism: Sulfonylureas close ATP -sensitive potassium channels (KATP) on pancreatic β-cells, causing persistent depolarization, calcium influx, and continuous exocytosis of endogenous insulin, independent of circulating glucose levels.
Clinical Danger: Administering IV dextrose boluses alone triggers further insulin release, leading to severe rebound hypoglycemia that can recur for 24 to 48 hours.
D10 vs. D50
Comparative Evidence & Pharmacological Rationale — Parenteral Dextrose: 10% Infusion vs. Hypertonic 50% Bolus — The Problem with 50% Dextrose (D50W): Concentrated 50% dextrose (500 mg/ml; osmolarity ≈2525 mOsm/L) is hyperosmolar.
Extravasation causes chemical tissue necrosis and compartment syndrome.
In addition, rapid D50W boluses cause hyperglycemia, stimulating counter-regulatory insulin release in patients with residual β -cell function and triggering reactive rebound hypoglycemia within 1 hour.
Advantage of D10
Advantage of 10% Dextrose (D10W): Administering 10% Dextrose (100–200 ml bolus; 10–20 g glucose) restores normoglycemia safely without severe hyperosmolality, lowers the risk of rebound hypoglycemia, and avoids extravasation necrosis.
Octreotide Antidote
Octreotide — The Antidote for Sulfonylurea Toxicity — Mechanism: Octreotide (Sandostatin) is a synthetic somatostatin analogue that binds to somatostatin receptor subtype-2 (SSTR-2) on pancreatic β-cells.
It blocks voltage-gated calcium channels, preventing calcium influx and halting sulfonylurea-stimulated insulin exocytosis.
Evidence (Fasano et al., Ann Emerg Med): In patients with sulfonylurea-induced hypoglycemia, subcutaneous or intravenous Octreotide significantly decreases recurrent hypoglycemic episodes, reduces IV dextrose infusion requirements, and shortens hospital length of stay compared to dextrose alone.
Glucagon
Glucagon — Utility & Limitations — Mechanism: Glucagon binds to hepatic G-protein-coupled receptors, stimulating glycogenolysis and gluconeogenesis to release glucose into the bloodstream.
Limitations: Ineffective in patients with depleted hepatic glycogen stores: chronic malnutrition, alcohol use disorder, prolonged fasting, or advanced cirrhosis.
It is slower than IV dextrose (10–15 minutes for clinical effect) and causes nausea and vomiting.
Its primary indication is emergent rescue when intravenous access cannot be established.
Administration: Administer 150–200 ml IV bolus over 10 to 15 minutes (delivers 15–20 g of elemental glucose).
Recheck point-of-care capillary glucose at 15 minutes.
If glucose remains <70 mg/dL, repeat another 100–150 ml bolus.
Follow with a continuous maintenance infusion of DEXTROSE 5% ALISON IV INFUSION 500ML or SODIUM CHLORIDE 0.9% & DEXTROSE 5% at 75–125 ml/hour to maintain blood glucose >100 mg/dL.
Dose: 1.0 mg IM or SC stat into the vastus lateralis or deltoid muscle.
Onset: Blood glucose increases within 10 to 15 minutes.
Establish IV access promptly during this window and provide oral carbohydrates as soon as consciousness is restored.
Stage 2 — Octreotide
Algorithm Stage 2: Antidotal Therapy for Sulfonylurea Toxicity Indicated for overdose or accidental ingestion of Glimepiride (AMARYL), Glibenclamide (GLUBEN), or Glipizide (GLUCORITE) with recurrent hypoglycemia despite dextrose:
Dosing Protocol: Initial Dose: 50–100 mcg Subcutaneously (or slow IV push over 5 minutes).
Maintenance Schedule: 50 mcg Subcutaneously every 6 to 12 hours for a minimum of 24 hours.
Monitoring Window: Sulfonylurea-induced hypoglycemia requires hospital admission and continuous monitoring for at least 24 to 48 hours.
Discontinue octreotide after 24 hours and observe the patient for an additional 12 to 24 hours off therapy without IV dextrose to confirm normoglycemia.
Red Flags & Safety Warnings • Do NOT Discharge Sulfonylurea Ingestions from the ER: Never discharge a patient with sulfonylurea-induced hypoglycemia based on rapid response to a single IV dextrose bolus. • The circulating sulfonylurea will stimulate prolonged insulin secretion, leading to recurrent severe hypoglycemia within hours, potentially resulting in irreversible hypoglycemic encephalopathy or death at home. • Admission for a minimum of 24 hours is mandatory. • Wernicke's Encephalopathy in Malnutrition/Alcohol Misuse: In patients with chronic alcoholism, cachexia, or severe malnutrition presenting with hypoglycemia, administer thiamine before or concurrently with intravenous glucose: • Formulary Match: THREE B'S DUOPACK (BPC, containing Thiamine HCl). • Mechanism: Glucose oxidation requires thiamine as a cofactor for pyruvate dehydrogenase. • Administering glucose without thiamine can precipitate acute Wernicke's encephalopathy (ataxia, ophthalmoplegia, acute confusion) or Korsakoff's psychosis.
Clinical Presentation & Risk Stratification Pathophysiology: Therapeutic Metabolism: At standard doses, >90% of paracetamol undergoes hepatic Phase II glucuronidation and sulfation to non-toxic metabolites excreted in urine.
Less than 5–10% is metabolized via Cytochrome P450 2E1 (CYP2E1) into the reactive electrophilic intermediate N -acetyl- p -benzoquinone imine (NAPQI).
NAPQI is rapidly conjugated with endogenous hepatic glutathione to non-toxic mercapturic acid conjugates.
Toxic Overdose Dynamics
Toxic Overdose Dynamics: Toxic ingestion (>150 mg/kg in children or >7.5–10 g>7.5–10 g in adults) saturates the glucuronide and sulfate pathways.
A larger fraction is shunted through CYP2E1, depleting hepatic glutathione stores.
Hepatotoxicity: When hepatic glutathione is depleted by >70%, free toxic NAPQI binds covalently to cysteinyl sulfhydryl groups on hepatocellular proteins, causing mitochondrial permeability transition, ATP collapse, acute centrilobular (Zone 3) hepatic necrosis, and liver failure.
Clinical Stages
Clinical Stages of Toxicity: Stage I (0.5–24 hours): Asymptomatic or mild nausea, vomiting, diaphoresis, malaise.
Normal liver function tests (AST/ALT normal).
Stage II (24–72 hours): "Quiescent phase." Gastrointestinal symptoms improve, but subclinical hepatotoxicity develops: right upper quadrant tenderness, hepatomegaly, and rising serum transaminases (AST/ALT elevation often >1000 IU/L>1000 IU/L), rising bilirubin, and prolonged PT/INR.
Comparative Evidence & Pharmacological Rationale — The Rumack-Matthew Nomogram Application: Validated only for single, acute paracetamol ingestions with known time of ingestion between 4 and 24 hours.
The Treatment Line: Begins at 150 mcg/ml () at 4 hours post-ingestion and ends at 4.7 mcg/ml () at 24 hours.
If the 4-hour serum paracetamol concentration is on or above the treatment line, antidote administration is mandatory.
Timing of Antidote: Initiating N -acetylcysteine (NAC) within ≤8 hours of an acute overdose provides near 100% hepatoprotection, reducing the risk of severe hepatotoxicity to <2–3% and mortality to near zero.
Hours Post-Ingestion — Antidote Mechanism: N-Acetylcysteine (NAC) Multiple Mechanisms of Action: Acts as a precursor for hepatic glutathione synthesis (supplies L-cysteine).
Acts as a direct glutathione substitute, binding and detoxifying reactive NAPQI directly.
Reduces NAPQI back to parent paracetamol.
Late Stage III/IV Benefit: In established acute liver failure, NAC acts as an antioxidant, free-radical scavenger, and microvascular vasodilator, improving cerebral and hepatic microcirculatory blood flow, oxygen extraction, and survival. Oral vs. Intravenous N-Acetylcysteine Formulations — Systematic Reviews: Both oral and intravenous NAC regimens have equivalent efficacy in preventing hepatotoxicity and death when initiated within 8 hours of ingestion.
Formulary Utilization: When IV NAC ampoules are not commercially stocked, oral acetylcysteine formulations (BONTRE 600 MG, REOLIN EFFERVESCENT 200MG) are guideline-approved substitutes.
Vomiting Management: Oral NAC has a foul, sulfurous odor and taste that triggers nausea.
Aggressive antiemetic pre-treatment with Ondansetron (ODNATRON) is required to prevent emesis and ensure full absorption.
1. Gastrointestinal Decontamination (Ingestions Within ≤2 Hours)
Formulary Match: EUCARBON TAB (Sukhtian, Activated Charcoal + Senna) or available bulk activated charcoal powder.
Dose: 50 g PO (or 1 g/kg).
Evidence: Activated charcoal administered within 1 to 2 hours of ingestion adsorbs paracetamol in the gastric lumen, decreasing systemic bioavailability by 50–90%.
Does not interfere with subsequent oral NAC if doses are separated.
2. Antiemetic Pre-Treatment (Mandatory Prior to Oral NAC)
Dissolve the required sachets/tablets into a chilled beverage (diet cola, orange juice, or water) to mask the sulfurous odor, making a 5% solution (50 mg/ml).
Loading Dose: 140 mg/kg PO once.
Calculation for 70 kg Adult: 70 kg ×140 mg/kg=9800 mg=9.8 g 70 kg×140 mg/kg=9800 mg=9.8 g.
Formulary Math: Dissolve 16 sachets of BONTRE 600 MG (9600 mg) in 200 ml chilled juice; drink over 10 minutes.
Maintenance Dosing: 70 mg/kg PO every 4 hours for a total of 17 maintenance doses (72 hours total).
Calculation for 70 kg Adult: 70 kg ×70 mg/kg=4900 mg=4.9 g 70 kg×70 mg/kg=4900 mg=4.9 g.
Formulary Math: Dissolve 8 sachets of BONTRE 600 MG (4800 mg) in 100 ml chilled juice; administer every 4 hours.
Emesis Rule: If the patient vomits within 1 hour of an oral dose, administer IV Ondansetron 8 mg and repeat the dose immediately.
Discharge Criteria & King\'s College Liver Transplant
Criteria for Safe Discharge/Discontinuation of NAC: Minimum of 21–24 hours of NAC therapy completed.
Serum Paracetamol level is undetectable (<10 mcg/ml).
KING\'S COLLEGE CRITERIA FOR LIVER TRANSPLANTATION IN PARACETAMOL OVERDOSE Arterial pH <7.30 at 24 hours (despite adequate fluid resuscitation)
OR All three of the following within a 24-hour period:
1. Grade III or IV hepatic encephalopathy
2. Serum Creatinine >3.4 mg/dL (>300 umol/L)
3. Prothrombin Time >100 seconds (INR >6.5) *Presence of these criteria confers >85% mortality without emergent transplantation.
Initiate urgent transfer to a specialized liver transplant critical care center.*
Red Flags & Safety Warnings • Chronic Supratherapeutic Ingestion: The Rumack-Matthew Nomogram cannot be used for repeated, chronic supratherapeutic ingestions (e.g., patient taking 6–8 g/day over several days for dental pain). • In repeated ingestions, if ALT/AST is elevated or paracetamol is detectable, initiate a full course of NAC regardless of nomogram lines. • Enhanced Toxicity Risk Factors: Patients with chronic malnutrition, chronic alcoholism, anorexia nervosa, HIV, or those taking CYP2E1-inducing medications (CARBAMAZEPINE, PHENOBARBITAL, TEGRETOL) have depleted baseline glutathione stores or upregulated CYP2E1 activity. • Toxicity in these patients can develop at much lower ingestions (>75–100 mg/kg or >4 g/day); treat with NAC at lower thresholds.
Clinical Presentation & Risk Stratification Pathophysiology: Virchow’s Triad (endothelial injury, stasis, hypercoagulability) driving fibrin-rich venous thrombus formation, typically within the deep calf or iliofemoral veins.
Detachment leads to embolization into the pulmonary arterial bed, causing mechanical obstruction, increased RV afterload, acute right ventricular dilatation, septal shift, and decreased left ventricular filling.
Stratification (ESC)
Stratification (ESC Guidelines on Acute Pulmonary Embolism):
High-Risk (Massive PE)
High-Risk (Massive PE): Hemodynamic instability (Systolic BP <90 mmHg for ≥15 minutes, vasopressors required, or cardiac arrest).
Requires immediate systemic thrombolysis or surgical embolectomy.
Intermediate-Risk (Submassive PE)
Hemodynamically stable, but exhibits both RV dysfunction on bedside echocardiography/CT and elevated cardiac biomarkers (Troponin/BNP).
Requires hospitalization and parenteral anticoagulation with readiness for rescue reperfusion.
Low-Risk PE / Uncomplicated DVT
Low-Risk PE/Uncomplicated DVT (PESI Class I–II or sPESI=0): Hemodynamically intact, normal RV, normal biomarkers.
Candidates for early ER discharge on oral Direct Oral Anticoagulants (DOACs).
DOAC Trials (EINSTEIN / AMPLIFY)
Comparative Evidence & Pharmacological Rationale — DOAC Monotherapy vs. Heparin/Vitamin K Antagonist (VKA) Bridging: The EINSTEIN-DVT/PE Trials (Rivaroxaban) & The AMPLIFY Trial (Apixaban):
Single Oral Drug Approach: Both Rivaroxaban (XARELTO) and Apixaban (Eliquis) are approved for upfront monotherapy without prior parenteral heparin lead-in, eliminating the need for inpatient IV heparin infusions or twice-daily subcutaneous enoxaparin injections.
Efficacy & Safety: In the AMPLIFY trial, oral Apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) in preventing recurrent VTE/death, while achieving a 69% relative reduction in major bleeding (0.6% vs. 1.8%; p<0.001).
The Loading Phase: Thrombus propagation is highest during the first 1 to 3 weeks.
High-dose upfront loading (Rivaroxaban 15 mg BID for 21 days, or Apixaban 10 mg BID for 7 days) provides rapid factor Xa inhibition to match the early hypercoagulable state before stepping down to maintenance therapy.
Cancer-Associated Thrombosis
Enoxaparin (LMWH) in Cancer-Associated Thrombosis (CAT) — The CLOT Trial: In patients with active malignancy presenting with VTE, Low Molecular Weight Heparin (Enoxaparin; CLEXANE) historically showed superior efficacy over VKAs in reducing recurrent thrombosis (HR 0.48).
While DOACs (Rivaroxaban/Apixaban) are now also guideline-approved for CAT, Enoxaparin remains the gold standard in gastrointestinal and genitourinary luminal cancers due to increased mucosal bleeding risks with DOACs.
Formulary Match: XARELTO 15MG 28 F.C.TAB (CEZAR) and XARELTO 20MG 28 F.C.TAB (CEZAR) or RIVOXAR (Jepharm).
Loading Dose: 15 mg PO twice daily for the first 21 days (Take with food; food increases bioavailability of doses ≥15 mg from 66% to nearly 100%).
Maintenance Transition: On Day 22, step down to 20 mg PO once daily with dinner.
2. Inpatient/Intermediate-Risk PE or Severe Renal Failure (Parenteral Regimen) — Enoxaparin Therapeutic Full Anticoagulation
Formulary Match: CLEXANE 100MG SAFETY LOCK SYR PREFIL or CLEXANE 80MG (MSS) or ENOXAPARIN LEDRAXEN 10000 IU (100MG)/1ML (True med).
Weight-Based Dose: 1 mg/kg Subcutaneously every 12 hours (or 1.5 mg/kg SC once daily).
Renal Failure Adjustment (CrCl <30 ml/min CrCl<30 ml/min): Reduce to 1 mg/kg SC once every 24 hours, or switch to Unfractionated Heparin (HEPARIN INJECTION BP 5000 UNITS/ML).
Scientific: Apixaban 5 mg. Sig: Take 2 tablets (10 mg) by mouth twice daily on Days 1 through 7; then take 1 tablet (5 mg) by mouth twice daily starting on Day
8. Duration: 3 months minimum for provoked VTE (transient risk factor); 6 months to indefinite for unprovoked VTE or active malignancy.
2. Patient Counseling: No routine coagulation/
INR monitoring required.
Report signs of significant bleeding (melena, hematuria, hemoptysis, severe hematoma).
Avoid concurrent OTC NSAIDs.
Red Flags & Safety Warnings • Massive PE with Hemodynamic Collapse: In high-risk PE with shock, systemic fibrinolysis (Alteplase) or surgical embolectomy is mandatory; DOACs are contraindicated in acute shock due to compromised splanchnic perfusion and unpredictable oral absorption. • Severe Renal Impairment (CrCl <15 ml/min CrCl<15 ml/min): DOACs are contraindicated. • Use dose-adjusted Unfractionated Heparin monitored by aPTT or anti-Xa levels.
Non-Purulent (Cellulitis, Erysipelas): Diffuse, spreading, flat erythematous inflammation without purulent drainage or fluctuance.
Caused primarily by β-hemolytic Streptococci (Streptococcus pyogenes), followed by Methicillin-Sensitive Staphylococcus aureus (MSSA).
Purulent (Abscess, Carbuncle, Furuncle)
Fluctuant, tender collection of pus with surrounding erythema.
Caused primarily by Staphylococcus aureus (including Community-Acquired MRSA).
Animal/Human Bites: Puncture or crush wounds inoculation with polymicrobial oral flora (Pasteurella multocida from cats/dogs; Capnocytophaga; Eikenella corrodens from humans).
Thermal Burns: Loss of epidermal barrier, microvascular thrombosis, and secondary colonization by S. aureus and Pseudomonas aeruginosa.
The Myth of Empiric MRSA Coverage for Typical Cellulitis: Over 85% of typical non-purulent cellulitis is mediated by Streptococci, against which trimethoprim-sulfamethoxazole and ciprofloxacin show high clinical failure rates.
Evidence: RCTs (e.g., Moran et al., NEJM) confirm that adding MRSA-targeted antibiotics to cephalexin does not increase cure rates in uncomplicated non-purulent cellulitis.
First-generation cephalosporins (Cephalexin; CEFALEX, CEFOVIT) remain the most effective first-line therapy.
Abscess — I&D First
Purulent Skin Abscess: Incision & Drainage vs. Antibiotics
Primary Intervention: The primary definitive treatment for a localized cutaneous abscess is complete incision, evacuation of pus, and disruption of loculations.
When Antibiotics Are Added: Systemic antimicrobials targeting CA-MRSA (Clindamycin; DALACIN C, DENACINE) are added if there is surrounding cellulitis (>2 cm), systemic inflammatory signs (fever, tachycardia), impaired host defenses, or extremes of age.
Clindamycin also inhibits bacterial ribosomal protein synthesis, suppressing the transcription of staphylococcal alpha-toxin and Panton-Valentine Leukocidin (PVL).
Bites — Co-Amoxiclav
Animal & Human Bites — Amoxicillin-Clavulanate Indication — Pathogen Vulnerability: Pasteurella multocida is naturally resistant to first-generation cephalosporins (cephalexin), clindamycin, and macrolides.
Formulary Choice: Amoxicillin-Clavulanate (Augmentin, Ecoclav) is the mandatory first-line agent, covering both Pasteurella and anaerobic oral flora (Fusobacterium, Bacteroides).
In-ER Pharmacotherapy (Immediate Resuscitation & Stabilization) — see steps below
Formulary Match (Part 1 — Broad Gram-Positive & Negative Coverage): CEFAZIN 1 GM VIAL (BPC) or CEFAZOLIN 1 G VIAL (Jepharm).
Dose: 1–2 g IV every 8 hours.
Part 2 — MRSA/Toxin
Formulary Match (Part 2 — If MRSA or Toxin-Mediated Necrotizing Infection Suspected): CLINDACIN 150MG/ML 4ML AMP (BPC) or DALACIN C 150MG/ML AMPOULES (Beit Hanina).
Dose: 600–900 mg IV every 8 hours (infused over 30 minutes).
Formulary Match: SILVEROL CREAM 50 GR TUB (Teva) or SILVEZIN CREAM 50gm (Beit Jala) (Scientific: Silver Sulfadiazine 1%).
Administration Protocol: Cleanse burn surface with sterile normal saline.
Apply a 2–4 mm thick layer directly to the burn or onto sterile gauze; reapply every 12 to 24 hours under sterile dressings.
Provides bactericidal activity against P. aeruginosa and S. aureus.
Contraindications: Do not use on the face (causes permanent cutaneous gray-black pigmentation/staining) or in patients with known sulfonamide hypersensitivity.
Red Flags & Safety Warnings • Necrotizing Fasciitis (Surgical Emergency): • "Pain out of proportion to physical exam findings," rapid progression over hours, skin bullae (especially hemorrhagic), cutaneous anesthesia, woody hard subcutaneous induration, or gas on soft-tissue radiograph/bedside ultrasound indicates necrotizing soft-tissue infection (NSTI). • Do not wait for CT confirmation or lab results. • Call General Surgery for emergent operative debridement and administer triple • IV broad-spectrum therapy: Piperacillin-Tazobactam (TAZO-PIP AVENIR 4.5G)+ Vancomycin (VANCOAVENIR 1G)+ Clindamycin (CLINDACIN 900MG IV to arrest toxin synthesis).
Clinical Presentation & Diagnostic Triage Pathophysiology: Retrograde ascent of uropathogens (predominantly Uropathogenic Escherichia coli [UPEC, 75–95%], Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis) from the perineum into the lower urinary tract (acute cystitis), ascending to the renal pelvis and parenchyma (acute pyelonephritis), or entering the prostatic ducts (acute bacterial prostatitis).
Acute Bacterial Prostatitis: High spiking fever, severe perineal/pelvic pain, dysuria, obstructive voiding symptoms (hesitancy, weak stream, acute urinary retention), exquisitely tender, boggy, hot prostate on gentle digital rectal examination (DRE).
Cystitis Options
Comparative Evidence & Pharmacological Rationale — Uncomplicated Cystitis: Single-Dose Fosfomycin vs. Nitrofurantoin vs. Fluoroquinolones:
FQ Stewardship
Fluoroquinolone Stewardship (FDA/EMA Warnings): Fluoroquinolones (Ciprofloxacin) should not be prescribed for uncomplicated cystitis due to adverse risks (tendon rupture, peripheral neuropathy, aortic aneurysm rupture, C. difficile colitis) and growing community E. coli resistance.
Fosfomycin Trometamol Superiority: Mechanism: Inhibits bacterial phosphoenolpyruvate synthetase, blocking the earliest step of bacterial peptidoglycan cell wall synthesis.
Excreted renally in high concentrations, remaining active in the bladder lumen for >48–72 hours after a single oral dose.
Evidence: A single 3 g sachet of Fosfomycin (FosfoClean, MONUROL) exhibits equivalent microbiological and clinical cure rates to multi-day regimens, achieves >95% adherence, and maintains activity against multi-drug resistant and ESBL-producing uropathogens.
Nitrofurantoin (Macrocarp)
Concentrates exclusively in the bladder urine with minimal systemic tissue penetration.
Renal Threshold: Ineffective in patients with eGFR <30 ml/min eGFR<30 ml/min due to insufficient urinary filtration, and contraindicated in pyelonephritis or prostatitis because it does not achieve therapeutic levels in renal parenchyma or prostatic tissue.
Pyelo/Prostatitis — Penetration
Pyelonephritis & Prostatitis — Tissue Penetration Requirements: Renal parenchyma and the lipid-rich prostatic epithelial barrier require lipophilic antimicrobials with high tissue penetration.
Third-generation cephalosporins (Ceftriaxone; SAMIXON) and Fluoroquinolones (Ciprofloxacin; CIPROCARE, Levofloxacin; LEVOX) distribute into renal and prostatic tissue, making them the standard first-line therapies.
Dose: 100–200 mg PO three times daily after meals for a maximum of 2 days.
Patient Education: Counsel patient that phenazopyridine turns urine a harmless, vivid reddish-orange color and can permanently stain clothing and contact lenses.
Sig: Take Ciprofloxacin 500 mg PO twice daily (or Levofloxacin 500 mg PO once daily).
Duration: 4 to 6 FULL WEEKS (Prolonged duration prevents chronic bacterial prostatitis and prostatic abscess).
Red Flags & Safety Warnings • Do NOT Massage or Vigorously Palpate the Prostate: In acute prostatitis, vigorous prostatic examination can force viable bacteria into the circulation, precipitating severe bacteremia and septic shock. • Obstructive Pyelonephritis: A patient with pyelonephritis who fails to defervesce within 48 to 72 hours of appropriate antibiotic therapy requires an urgent renal ultrasound or CT to evaluate for an obstructing ureteral calculus, perinephric abscess, or renal parenchymal phlegmon.
Severe Pre-Eclampsia: New-onset hypertension (SBP ≥160 mmHg SBP≥160 mmHg or DBP ≥110 mmHg DBP≥110 mmHg on two occasions ≥4 hours apart) after 20 weeks gestation, accompanied by proteinuria or acute target-organ features (headache, visual scotoma, RUQ/epigastric pain, pulmonary edema, platelet count <100,000/μL<100,000/μL, creatinine >1.1 mg/dL).
Eclampsia: Development of generalized tonic-clonic convulsions or unexplained coma in a pre-eclamptic patient.
2. Postpartum Hemorrhage (PPH): Cumulative blood loss ≥1000 ml or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours of delivery.
The leading cause is uterine atony (>80%).
3. Pelvic Inflammatory Disease (PID): Polymicrobial infection ascending from the cervix (Neisseria gonorrhoeae, Chlamydia trachomatis, anaerobes).
Pelvic or lower abdominal pain accompanied by cervical motion tenderness ("chandelier sign"), uterine tenderness, or adnexal tenderness on bimanual pelvic examination.
The Magpie Trial (Lancet): Demonstrated that Magnesium Sulfate cuts the risk of eclampsia by more than half (58% reduction; RR 0.42) and reduces maternal mortality compared to placebo.
The Eclampsia Trial (Lancet)
Magnesium Sulfate was significantly superior to both Diazepam and Phenytoin in terminating recurrent seizures, preventing future convulsions, and lowering maternal and neonatal mortality.
Mechanism: Blocks neuronal N-methyl-D-aspartate (NMDA) receptors, induces cerebral vasodilation to relieve maternal cerebral ischemia, and stabilizes vascular endothelial membranes.
PPH — Uterotonics & TXA
PPH — Uterotonics & Tranexamic Acid (The WOMAN Trial) — Oxytocin Backbone: Primary physiologic uterotonic; binds G-protein-coupled oxytocin receptors on uterine myometrium, triggering rhythmic contractions to compress open intramyometrial spiral arterioles.
The WOMAN Trial (Lancet)
Early administration of intravenous Tranexamic Acid (TXA; HEXAKAPRON) within 3 hours of delivery reduced death due to bleeding by 31% in women with postpartum hemorrhage without increasing thromboembolic events.
Pelvic Inflammatory Disease — The CDC Empiric Regimen: Empiric treatment must be initiated immediately upon recognizing cervical motion tenderness to prevent chronic pelvic pain, ectopic pregnancy, and tubal infertility.
The CDC guidelines mandate a 3-drug regimen: Ceftriaxone (anti-gonococcal)+ Doxycycline (anti-chlamydial)+ Metronidazole (anti-anaerobic and Trichomonas coverage).
Preparation: Draw 8 ml (4 g) of 50% MgSO4; dilute in 100 ml of SODIUM CHLORIDE 0.9% 100 ML or DEXTROSE 5% 100ML.
Infuse over 20 minutes.
Maintenance Infusion: Follow immediately with a continuous IV infusion of 1–2 g/hour (2–4 ml/hr of 50% diluted appropriately in IV fluids) for 24 hours post-delivery or post-last seizure.
Antidote for Toxicity: If patellar deep tendon reflexes are lost, or respiratory rate <12 breaths/min, stop the infusion and administer Calcium Gluconate 10% (10 ml IV over 3 minutes): CALCIUM GLUCONATE 10% 10 ML 20 AMP (MSS).
If BP remains ≥160/110 mmHg after 10 minutes, administer 40 mg, then 80 mg every 10 minutes (max 300 mg).
2. Postpartum Hemorrhage (PPH) Medical Resuscitation
Administer medical therapies concurrently while performing manual uterine fundal massage:
Step 1 — Oxytocin
Step 1: Primary Uterotonic (Oxytocin Infusion):
Formulary Match: OXYTOCIN INJECTION BP 10AMP (10IU/ML) (True med) or OXYTOCIN - GRINDEKS 10IU/1 ML (Medimarket).
Dose: Add 20–40 Units (2–4 ampoules) into 1000 ml of COMPOUND SODIUM LACTATE 500 ML or 0.9% NaCl.
Infuse at 250–500 ml/hour (titrated to maintain firm uterine tone).
Safety Rule: Never administer undiluted oxytocin as a rapid IV push; bolus injections cause systemic vasodilation, profound hypotension, and reflex tachycardia.
Step 2 — TXA
Step 2: Antifibrinolytic (Tranexamic Acid — The WOMAN Protocol):
Counseling: Abstain from sexual intercourse until both patient and partners are fully treated.
Avoid alcohol during and for 48 hours post-metronidazole (disulfiram-like reaction).*
Red Flags & Safety Warnings • Ruptured Ectopic Pregnancy: Any female of reproductive age presenting with lower abdominal pain, vaginal bleeding, or syncope must receive a point-of-care urine or serum β-hCG test immediately. • If positive with peritoneal signs or hypotension, perform a bedside FAST ultrasound to assess for hemoperitoneum; call Obstetrics/Gynecology for emergent laparoscopy/laparotomy and crossmatch packed red blood cells.
Pathophysiology: Sudden pupillary block trapping aqueous humor in the posterior chamber, bowing the peripheral iris forward over the trabecular meshwork, abruptly occluding the iridocorneal drainage angle.
Intraocular pressure (IOP) rises rapidly from normal (10–21 mmHg) to >40–70 mmHg.
Physical findings include a steamy/cloudy cornea, conjunctival ciliary injection, a mid-dilated, non-reactive pupil, and a globe that feels hard on gentle palpation.
2. Bacterial Keratitis (Infected Corneal Ulcer):
Pathophysiology: Disruption of corneal epithelium (frequently contact lens wearers) leading to bacterial colonization (Pseudomonas aeruginosa, S. aureus).
Appears as a white focal corneal infiltrate with an overlying epithelial defect that lights up with fluorescein staining.
AACG — Multi-Target Strategy
Comparative Evidence & Pharmacological Rationale — Acute Angle-Closure: The Multi-Target Pressure Reduction Strategy: Monotherapy fails to resolve pupillary block.
Osmotic Extraction of Vitreous Water: Mannitol (MANNITOL 20%) dehydrates the vitreous body, drawing it backward and relieving pressure on the iris diaphragm.
Reversing Iris Apposition (Miosis)
Topical pilocarpine pulls the peripheral iris away from the trabecular meshwork (effective only after IOP falls below 40–50 mmHg, at which point the ischemic iris sphincter recovers function).
Sig: Instill 1 drop into the affected eye every 1 hour while awake for the first 48 hours; then instill 1 drop every 2 hours until seen by Ophthalmology.
Alternative: CILOXAN EYE DROPS (Ciprofloxacin 0.3%) OR ZYMAXID Ophth. Sol 5% (Gatifloxacin).*
2. Topical Cycloplegic/Spasmolytic (For Severe Ciliary Spasm Pain):
Sig: Instill 1 drop into the affected eye twice daily.
Relieves pupillary spasm.
3. Strict Warning: Do NOT use topical corticosteroids (Pred Forte, DEXA-ALISON) in active epithelial ulcers; steroids accelerate stromal melting, potentiate fungal growth, and risk corneal perforation.
Do NOT wear contact lenses until cleared by an ophthalmologist.
Red Flags & Safety Warnings • Contraindication of Timolol Drops in Severe Asthma: Topical β-blockers administered via the conjunctival sac drain through the nasolacrimal duct and are absorbed directly into the systemic venous circulation via nasal mucosal capillaries, bypassing first-pass hepatic metabolism. • A single drop of 0.5% Timolol can precipitate severe bronchospasm or status asthmaticus in patients with severe asthma or COPD. • Verify respiratory history before administration.
Pathophysiology: Common in rural and agricultural regions in Palestine.
Irreversible inhibition of acetylcholinesterase (AChE), causing systemic accumulation of acetylcholine at muscarinic and nicotinic receptors and within the CNS.
Leading Cause of Death: Asphyxiation from the "killer B's": Bronchorrhea, Bronchospasm, and Bradycardia.
Agitation — FGA vs. SGA (TREC)
Comparative Evidence & Pharmacological Rationale Acute Agitation: First-Generation (Haloperidol) vs. Second-Generation Antipsychotics (Olanzapine) TREC Trials (Lancet): Evaluated rapid tranquilization in severe agitation.
Intramuscular or rapidly dissolving oral second-generation antipsychotics (Olanzapine; ZYPREXA VELOTAB) achieve effective sedation comparable to Haloperidol, but with a significantly lower incidence of Extrapyramidal Symptoms (EPS) and acute dystonias (1.5% vs. 12%).
Benzodiazepine Combination: Combining an antipsychotic with a benzodiazepine (ZYPREXA or PERIDOL + LORIVAN or SEREPAM) achieves sedation faster, requires fewer re-dosing events, and protects against antipsychotic-induced lowering of the seizure threshold.
Atropine Doubling Protocol
Organophosphates — The Atropine Doubling Protocol — Atropine is the Primary Life-Saving Drug: Competitively blocks muscarinic acetylcholine receptors.
The Doubling Protocol (Pawar et al., Lancet): Small fixed doses fail to overcome toxic organophosphate loads.
The protocol dictates: Start with 1–2 mg IV; if no clinical response within 3 to 5 minutes, double the dose (2 mg→4 mg→8 mg→16 mg→32 mg 2 mg→4 mg→8 mg→16 mg→32 mg), until muscarinic signs resolve.
Clinical Target: Atropinization is defined by: Clearing of bronchial secretions, cessation of bronchospasm, heart rate >80 bpm, and Systolic BP >80 mmHg.
Formulary Match: PERIDOL 5 MG 20 TAB (oral) or for parenteral emergency sedation: MIDOLAM 5MG/ML AMP/5 AMP (Syam) or MIDAZOLAM KALCEKS 5MG/ML (Medimarket).
Dose: 5 mg IM stat (or 2.5–5 mg slow IV push).
Rapid onset within 5 to 10 minutes.
Alternative (Diazepam)
SEREPAM 10 MG AMP 5 AMP (BPC): 5–10 mg slow IV push (avoid IM diazepam due to erratic tissue absorption).
Antidote for Antipsychotic-Induced Acute Dystonic Reactions (Oculogyric Crisis/Torticollis)
Formulary Match: DEKINET 2MG TABS/30 (Syam) or ARTIDYL 2 MG (Jepharm) (Scientific: Biperiden HCl or Trihexyphenidyl 2 mg).
Dose: 2–4 mg PO or IM/IV stat.
Reverses acute extrapyramidal muscular spasms within 15 to 30 minutes.
2. Antidotal Resuscitation: Organophosphate/Carbamate Poisoning — Personal Protective Equipment (PPE) is mandatory before touching the patient; dermal absorption can contaminate healthcare workers.
Remove and double-bag all clothing; wash skin with soap and water.
Assessment & Escalation: Reassess every 3 to 5 minutes for bronchial secretions and heart rate.
The Doubling Rule: If lung fields remain wet with heavy secretions, double the previous dose: 2 mg⟶4 mg⟶8 mg⟶16 mg⟶32 mg 2 mg⟶4 mg⟶8 mg⟶16 mg⟶32 mg
Maintenance Infusion: Once atropinization is achieved (lungs clear to auscultation, bronchospasm resolved, heart rate >80 bpm), set up a continuous IV infusion delivering 10–20% of the total bolus dose required per hour to maintain stable receptor saturation for 24 to 48 hours.
Red Flags & Safety Warnings • Atropine and Hypoxia: Administering atropine to an anoxic, severely hypoxic patient can trigger ventricular fibrillation. • Oxygenate the patient with high-flow oxygen and perform bag-valve-mask suctioning concurrently with the initial atropine doses. • Do NOT Give Succinylcholine for • Intubation in Organophosphate Poisoning: Organophosphates inhibit plasma pseudocholinesterase (butyrylcholinesterase), the enzyme responsible for degrading succinylcholine. • Administering succinylcholine will cause neuromuscular blockade and diaphragmatic paralysis that can persist for hours to days. • Use Rocuronium (Rocuronium bromide kalceks 10mg/ml) instead.
Comparative Evidence & Pharmacological Rationale — Combination Therapy (β-Lactam + Macrolide) vs. Respiratory Fluoroquinolone Monotherapy — The Inpatient Non-ICU Dilemma: ATS/IDSA CAP Guidelines: Both a β -lactam plus a macrolide (e.g., Ceftriaxone + Azithromycin) and a respiratory fluoroquinolone (e.g., Levofloxacin or Moxifloxacin monotherapy) are approved first-line options for hospitalized non-ICU patients.
Evidence (Sligl et al., Crit Care Med): Multiple large observational cohorts and meta-analyses demonstrate that combination therapy with a macrolide yields a statistically significant reduction in 30-day mortality compared to non-macrolide regimens.
Mechanism of Macrolide Benefit: Beyond direct bacteriostatic action at the 50S ribosomal subunit, macrolides (Azithromycin; AZICARE, ZITROCIN) exert immunomodulatory/anti-inflammatory effects: they downregulate excessive neutrophil activation, decrease interleukin-8 (IL-8) transcription, reduce pulmonary vascular leak, and suppress biofilm formation.
Outpatient Monotherapy
Outpatient Monotherapy: Amoxicillin vs. Doxycycline vs. Macrolides
Why Amoxicillin 1 g TID is First-Line: High-dose Amoxicillin (AMOXICARE 1000 MG) achieves alveolar epithelial lining fluid concentrations exceeding the MIC of over 90% of intermediate and resistant Streptococcus pneumoniae isolates.
Doxycycline Utility: Doxycycline (DOXYLIN, DOXAL) inhibits bacterial protein synthesis via the 30S subunit, maintaining activity against S. pneumoniae while providing atypical coverage (Mycoplasma, Chlamydia).
It is preferred when penicillin allergy is present.
Macrolide Monotherapy Warning: Azithromycin monotherapy is no longer recommended in areas where pneumococcal macrolide resistance exceeds 25% (widespread in the Middle East/Mediterranean region), unless restricted to young, healthy patients with confirmed atypical presentations.
Aspiration — Pneumonitis vs. Pneumonia
Aspiration Pneumonitis vs. Aspiration Pneumonia — Aspiration Pneumonitis (Mendelson\'s Syndrome): Chemical burn of the tracheobronchial tree caused by acidic gastric contents.
Occurs abruptly within 2 hours of witnessed vomiting/aspiration.
Antibiotics are contraindicated initially; treatment is supportive suctioning and oxygenation.
Aspiration Pneumonia: Occurs 48–72 hours later, when colonized oropharyngeal secretions produce secondary bacterial infection in dependent lung segments (superior segments of lower lobes, posterior segments of upper lobes).
Anaerobic Coverage Evidence: Modern studies show anaerobic mouth flora (Bacteroides, Fusobacterium) are secondary players compared to typical oral streptococci and enteric Gram-negatives.
Routine clindamycin is no longer required; Amoxicillin-Clavulanate (Augmentin 875mg) or Ceftriaxone + Metronidazole provides balanced coverage.
Formulary Match (Part 1 - Beta-Lactam): SAMIXON 1000 MG IV (Pharmacare Store) or CEFIXON 1G VIAL (BPC) (Scientific: Ceftriaxone Sodium 1 g).
Dose: 1000–2000 mg (1–2 g) IV once daily infused in 100 ml 0.9% NaCl over 30 minutes.
Formulary Match (Part 2 — Macrolide)
AZITHROMYCIN MBI 500 MG/VIAL 1 VIAL (Beit Al-Dawaa) or ZITHROMAX 500 mg/Vial (Beit Hanina) (Scientific: Azithromycin 500 mg).
Dose: 500 mg IV once daily infused over 60 minutes. (Oral switch alternative if patient tolerates fluids: AZICARE 500 MG PO daily).
Option B — Fluoroquinolone
Option B — Respiratory Fluoroquinolone Monotherapy (Penicillin-Allergic Patient):
Formulary Match: LEVOX 500MG TABLETS (Jepharm) or TAVANIC 500 MG (MSS) or CIPROFLOXACIN I.V ALTAN (or IV Levofloxacin).
Dose: Levofloxacin 500–750 mg IV/PO once daily; OR Formulary Match: MEGAXIN IV 400MG/250ML (CEZAR) or MOXIFLOX 400 MG TABLETS (Pharmacare) (Scientific: Moxifloxacin 400 mg).
Dose: 400 mg IV or PO once daily.
Category 2 — Severe / ICU
Category 2: Severe CAP Requiring ICU Admission (CURB-65 ≥3, Septic Shock, or Mechanical Ventilation) Combination therapy is mandatory; monotherapy is associated with higher mortality.
Step 1 (Core Backbone)
SAMIXON 1000 MG IV (Pharmacare Store): 2000 mg (2 g) IV once daily; PLUS
Step 2 (Macrolide Immunomodulation)
AZITHROMYCIN MBI 500 MG/VIAL: 500 mg IV once daily.
Step 3 (Add if Pseudomonas aeruginosa Risk Factors Present: Structural lung disease, severe COPD, bronchiectasis)
Replace Ceftriaxone with: TAZO-PIP AVENIR 4.5G 1VIAL/50ML (Beit Al-Dawaa) at 4.5 g IV every 6 hours; OR MERO-AVENIR VIAL 1000MG (Beit Al-Dawaa) at 1 g IV every 8 hours.
Add VANCOAVENIR VIAL 1G (Beit Al-Dawaa): Loading dose of 25–30 mg/kg IV (infused at ≤10 mg/min in 500 ml 0.9% NaCl), followed by 15–20 mg/kg IV every 8 to 12 hours.
Regimen B: Outpatient with Chronic Comorbidities (COPD, Diabetes, Heart Failure, Renal Disease, or Age ≥65) Must cover both resistant S. pneumoniae and atypical organisms.
Red Flags & Safety Warnings • Delayed Clinical Stability: Clinical stability (afebrile, heart rate <100 bpm, respiratory rate <24, SpO2 ≥92%) should occur within 48 to 72 hours. • Failure to improve mandates a repeat chest radiograph or CT to evaluate for parapneumonic effusion, lung abscess, or central bronchial obstruction. • Fluoroquinolone QT Prolongation: Moxifloxacin and Levofloxacin can prolong the myocardial QTc interval. Avoid in patients with baseline QTc >480 ms, hypokalemia, or those taking concurrent QTc-prolonging drugs (AMIOCARD, ODNATRON).
2. ACUTE SEVERE ADULT ASTHMA (STATUS ASTHMATICUS) 1
Steroid in 1 hourGINA · 3Mg▾
2. ACUTE SEVERE ADULT ASTHMA (STATUS ASTHMATICUS)
Continuous SABA + ipratropium · IV magnesium · MART discharge
Background talk — triage, SABA & steroids
Clinical Presentation & Severity Triage Pathophysiology: Acute-on-chronic airway hyperresponsiveness, smooth muscle bronchospasm, inflammatory microvascular plasma exudation, and extensive intraluminal mucoid impaction leading to dynamic airflow obstruction and intrinsic positive end-expiratory pressure (auto-PEEP).
Severity Triage (GINA Guidelines)
Mild-to-Moderate: Speaks in phrases, prefers sitting to lying, not agitated, respiratory rate increased, heart rate 100–120 bpm, SpO2 90–95%, accessory muscle use moderate.
Severe: Speaks in single words, sits hunched forward, agitated, respiratory rate >30 breaths/min, heart rate >120 bpm, SpO2 <90% on ambient air, prominent sternocleidomastoid retractions, loud expiratory and inspiratory wheezes.
Life-Threatening/Impending Arrest: Drowsy, confused, paradoxical thoracoabdominal breathing, "silent chest" on auscultation, bradycardia, or exhaustion.
Continuous vs. Intermittent SABA
Comparative Evidence & Pharmacological Rationale — Continuous vs. Intermittent SABA Nebulization — Evidence (Cochrane Systematic Review): Continuous nebulization of Salbutamol (10–15 mg/hour) in severe acute asthma produces greater improvements in FEV1 and peak expiratory flow (PEF) at 2 hours and significantly reduces hospital admission rates compared with intermittent nebulization alone.
Steroids — Timing & Route
Systemic Corticosteroids — Timing & Route: Timing: Systemic corticosteroids must be administered within the first hour of ER arrival. Delays >1 hour increase hospital admission rates and prolong recovery time.
Oral vs. IV Equivalence: Multiple randomized double-blind trials demonstrate that oral administration of prednisolone/prednisone (50 mg) has identical pharmacokinetic efficacy and clinical outcomes to IV methylprednisolone (60–120 mg), as oral bioavailability exceeds 85–90%.
Reserve the IV route for patients unable to swallow, vomiting, in respiratory exhaustion, or on non-invasive/invasive mechanical ventilation.
IV Magnesium (3Mg Trial)
Intravenous Magnesium Sulfate in Severe Adult Asthma — The 3Mg Trial (Goodacre et al., Lancet Respir Med): Evaluated IV versus nebulized magnesium in severe acute asthma.
IV Magnesium Sulfate (2 g infused over 20 minutes) significantly improved pulmonary function and reduced hospital admissions in adults presenting with severe acute exacerbations (PEF <50% PEF<50% predicted or SpO2 <92%).
Nebulized magnesium showed no significant clinical benefit over IV administration.
Preparation & Infusion: Add 4 ml of 50% MgSO4 to 100 ml of SODIUM CHLORIDE 0.9% INTRAVENOUS INFUSION BP BAGS 100 ML (Teva).
Infuse IV over 20 minutes under continuous cardiac telemetry and blood pressure monitoring.
Discharge & Outpatient Transition Regimen
Discharge Criteria: PEF >70–75% predicted/personal best, sustained SpO2 ≥94% on ambient air for >3 hours post-bronchodilator, minimal work of breathing, access to home medications verified.
Sig: Inhale 2 puffs twice daily (morning and evening); rinse mouth after inhalation.
MART Protocol (Maintenance and Reliever Therapy)
May use 1 additional puff as needed for breakthrough symptoms in place of a separate SABA inhaler.*
Red Flags & Safety Warnings • The "Normal" P aCO 2 PaCO2 Trap: A severe asthmatic who is hyperventilating should physiologically have a low arterial/venous P aCO 2 PaCO2 (<35 mmHg). • If blood gas reveals a "normal" P aCO 2 PaCO2 (40–45 mmHg) or rising acidosis, this does not indicate normalization. • It indicates respiratory muscle fatigue, failure of alveolar ventilation, and impending respiratory arrest. • Prepare for intubation. • Complications of Intubation in Asthma: Intubation in status asthmaticus carries high morbidity and mortality from dynamic hyperinflation, breath-stacking, pneumothorax, and sudden cardiovascular collapse from elevated intrathoracic pressure obstructing venous return. • Reserve intubation for coma, apnea, or refractory exhaustion. • If intubated, use low respiratory rates (8–10 breaths/min), low tidal volumes (6–8 ml/kg), and prolonged expiratory times (I:E=1:4 or 1:5) to allow complete exhalation.
Pathophysiology & The Vicious Cycle — The Mechanism: An acute, sympathetic-driven hypertensive emergency occurring over minutes to hours.
Severe, abrupt systemic vasoconstriction drives afterload to extreme levels (Systolic BP often >200–240 mmHg).
Fluid Redistribution: The primary pathology is not total-body volume overload; it is acute fluid redistribution.
High afterload forces blood backward from the systemic resistance vessels into the pulmonary vascular bed, flooding pulmonary capillaries within minutes.
The Vicious Cycle: Acute pulmonary edema triggers air hunger and sympathetic storm, which drives more vasoconstriction, worsening afterload and fluid transudation.
THE PATHOPHYSIOLOGIC SCAPE CYCLE Sympathetic Surge/Extreme HTN (SBP >200 - 240 mmHg) │ ▼ Severe Systemic Vasoconstriction (Massive Afterload) │ ▼ Impaired LV Ejection/Elevated LVEDP │ ▼ Central Fluid Shift into Lungs (Flash) │ ▼ Hypoxemia, Dyspnea, and Panic │ ▼ Further Sympathetic Surge (Reinforcement)
Comparative Evidence: High-Dose Nitrates vs. Loop Diuretics — The Danger of High-Dose Diuretics in SCAPE
Because SCAPE is a fluid-redistribution crisis rather than a volume-overload state, administering large IV furosemide boluses (80–160 mg) without afterload reduction fails to resolve pulmonary edema and can cause acute intravascular hypovolemia, profound hypotension, and acute kidney injury once afterload relaxes.
Evidence (Levy et al., Ann Emerg Med): High-dose intravenous nitrates administered rapidly to target afterload reduction resolve dyspnea faster, reduce endotracheal intubation rates by >75%, and reduce ICU admissions compared to standard-dose diuretics.
In-ER Pharmacotherapy (Immediate Resuscitation) — see below
SCAPE RESUSCITATION SEQUENCE Step 1: Non-Invasive Positive Pressure Ventilation (BiPAP/CPAP) (Immediately recruits alveoli, increases functional residual capacity, and reduces LV transmural afterload) │ ▼ Step 2: Aggressive Vasodilation (High-Dose Nitrate Therapy) (Shifts fluid from pulmonary circulation back to peripheral capacitance vessels; abruptly lowers afterload) │ ▼ Step 3: Low-Dose Loop Diuretic (Delayed Adjunct) (Administer small-dose furosemide ONLY after afterload is broken)
Apply BiPAP mask immediately: Start at IPAP=10–12 cmH2O and EPAP=5 cmH2O; titrate rapidly to IPAP=15–18, EPAP=8–10 cmH2O.
Dose: 20–40 mg PO/sublingual stat. (If IV Nitroglycerin is available: Bolus 400–1000 mcg IV over 2 minutes, followed by an infusion titrated rapidly at 100–300 mcg/min until SBP drops by 20–25%).
Dose: 20–40 mg IV bolus only (Administer after nitrates and BiPAP have begun lowering blood pressure and afterload; do not rely on diuresis to treat the acute flash edema).
Scenario B — Sympathomimetic Crisis
SCENARIO B — SYMPATHOMIMETIC-INDUCED HYPERTENSIVE CRISIS (COCAINE/AMPHETAMINES) — Pathophysiology & The Unopposed α-Stimulation Debate: Pathophysiology: Cocaine blocks the presynaptic reuptake of norepinephrine, dopamine, and epinephrine.
Amphetamines stimulate the active presynaptic release of catecholamines.
This produces profound peripheral α1 -mediated arterial vasoconstriction, β1 -mediated inotropic and chronotropic drive, severe coronary vasoconstriction, and platelet activation.
The Unopposed α -Stimulation Paradigm: The Physiological Hazard: Administering a pure, non-selective β -blocker (such as Propranolol; PROLOL) blocks vasodilatory β2-adrenergic receptors in vascular beds while leaving α1-adrenergic receptors fully occupied by excess catecholamines.
This can cause unopposed α-adrenergic vasoconstriction, driving blood pressure higher and exacerbating coronary artery spasm.
Modern Consensus (AHA Guidelines)
Pure β-blockers are contraindicated in the acute phase of cocaine/amphetamine toxicity.
First-Line Class: Benzodiazepines are the first-line therapy.
Benzodiazepines enhance central GABA-A receptor transmission, suppressing centrally driven sympathetic outflow, lowering blood pressure, reducing tachycardia, and resolving psychomotor agitation.
Second-Line Antihypertensive: If severe hypertension persists despite high-dose benzodiazepines, use Labetalol (LABETALOL AMP 5MG/ML—which possesses combined α1 - and β -blocking activity with a favorable α: β α:β ratio) or Calcium Channel Blockers (ADIZEM [Diltiazem] or VERAPRESS [Verapamil]).
In-ER Pharmacotherapy (Immediate Resuscitation) — see below
SCENARIO C — OUTPATIENT STEP-CARE INITIATION FOR ASYMPTOMATIC HYPERTENSION — Pathophysiology & Initiation Thresholds — Definition: Confirmed persistent blood pressure ≥140/90 mmHg (Stage 1:130–139/80–89 130–139/80–89; Stage 2: ≥140/90 mmHg) without acute target-organ damage (normal renal function, no acute retinopathy, no chest pain, no focal neurological deficits).
AHA/ESH Guideline Recommendation: In patients with Stage 2 Hypertension (BP ≥140/90 mmHg BP≥140/90 mmHg, and especially if >20/10 mmHg over target), initiate therapy with two first-line agents of different classes simultaneously, ideally as a fixed-dose combination.
Upfront combination therapy achieves blood pressure control substantially faster than step-wise monotherapy titration.
Class Synergy (ACCOMPLISH)
Comparative Evidence — Class Synergy: ACE Inhibitor/ARB + Dihydropyridine Calcium Channel Blocker (CCB) — The ACCOMPLISH Trial (Jamerson et al., NEJM): Demonstrates that an ACE inhibitor combined with a CCB (Amlodipine) is superior to an ACE inhibitor combined with a thiazide diuretic in reducing cardiovascular events and death (RRR 20%).
Edema Neutralization Mechanism: Amlodipine causes preferential precapillary arteriolar vasodilation, increasing capillary hydrostatic pressure and leading to peripheral ankle edema.
Adding an ACE inhibitor or ARB induces balanced post-capillary venodilation, normalizing hydrostatic pressure and reducing amlodipine-induced peripheral edema by >50%.
Full verbatim text of the PALMEDICS Adult Emergency Protocols (Modules 2–5 plus Expansion) — formulated exclusively with the Palestinian local formulary. Brands verified in stock. Educational quick-reference only — verify against full texts, product labels, local resistance and the individual patient; refer/admit severe, atypical or non-responding cases.
Continuing the series — Module 3 (GI / Neuro / Pain) is now live: open Module 3 below ↓ • Continuing the Series We have completed: Module 1: Pediatric Emergency Medicine Protocols Module 2: Acute Adult Cardiorespiratory, Vascular & Shock Emergencies The logical next step is Module 3: Acute Adult Gastrointestinal, Neurological & Pain Emergencies, covering: Acute Upper Gastrointestinal Bleeding (peptic ulcer vs. variceal: IV PPI infusions, terlipressin, octreotide, prophylactic ceftriaxone, and erythromycin prokinetics). • Acute Pancreatitis & Intra-Abdominal Sepsis (fluid optimization, analgetic selection, and targeted surgical antimicrobial coverage). • Acute Ischemic Stroke & Transient Ischemic Attack (TIA) (early dual antiplatelet strategies based on the POINT and CHANCE trials, permissive hypertension parameters, and secondary neuroprotection). • Refractory Migraine & Status Migrainosus (the emergency "migraine cocktail": parenteral NSAID + dopamine receptor antagonist + dexamethasone to prevent recurrence vs. triptans and gepants). • Acute Renal Colic/Nephrolithiasis (IV NSAIDs vs. opioids, antiemetics, and medical expulsive therapy with selective α1-blockers).
Series status — Module 4 (endocrine/tox) is now live: open Module 4 below ↓ • Series Status & What Follows We have completed: Module 1: Pediatric Emergency Medicine Protocols Module 2: Acute Adult Cardiorespiratory, Vascular & Shock Emergencies Module 3: Acute Adult Gastrointestinal, Neurological, Surgical & Pain Emergencies The logical next step is Module 4: Acute Adult Endocrine, Toxicological, Environmental & Electrolyte Emergencies, which will cover: Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS): Fluid resuscitation paradigms, IV regular insulin titration protocols (INSU.ACTRAPID VIAL), potassium replacement strategies (POTASSIUM CHLORIDE 14.9%), and the bicarbonate debate. • Severe Acute Hyperkalemia: Membrane stabilization (CALCIUM GLUCONATE 10%), intracellular potassium shifting (INSU.ACTRAPID + DEXTROSE 10%/VENTOLIN RESP.SOL.), and potassium elimination (KAYEXALATE POWDER, Veltassa 16.8 sachet, FURO-ALISON). • Acute Opioid & Benzodiazepine Overdose/Toxidromes: Reversal strategies, dosing titrations to avoid precipitated acute withdrawal, and observation windows. • Acute Poisonings & Ingestions: Paracetamol (acetaminophen) toxicity and early rescue.